EP2352734A1 - Tricyclic nitrogen compounds used as antibacterials - Google Patents

Tricyclic nitrogen compounds used as antibacterials

Info

Publication number
EP2352734A1
EP2352734A1 EP09740103A EP09740103A EP2352734A1 EP 2352734 A1 EP2352734 A1 EP 2352734A1 EP 09740103 A EP09740103 A EP 09740103A EP 09740103 A EP09740103 A EP 09740103A EP 2352734 A1 EP2352734 A1 EP 2352734A1
Authority
EP
European Patent Office
Prior art keywords
dihydro
methyl
alkyl
pyridin
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09740103A
Other languages
German (de)
French (fr)
Inventor
Ilaria Giordano
Alan Joseph Hennessy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of EP2352734A1 publication Critical patent/EP2352734A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • This invention relates to novel compounds, compositions containing them and their use as antibacterials.
  • WO08006648, WO08003690 and WO08009700 disclose quinoline, naphthyridine, morpholine, cyclohexane, piperidine and piperazine derivatives having antibacterial activity.
  • WO2004104000 discloses tricyclic condensed ring compounds capable of selectively acting on cannabinoid receptors.
  • WO2003048081 , WO2003048158 and US2003232804 disclose glycinamides as Factor Xa inhibitors.
  • This invention provides a compound of formula (I) or a pharmaceutically acceptable salt and/or N-oxide thereof:
  • Z 1 and Z 2 are CR 1c and the other is CH or N;
  • R ⁇ a and R-" 3 are independently selected from hydrogen; halogen; cyano; (C-
  • R 1 c is (C-
  • R 2 is hydrogen, (C-
  • A is a group (i) selected from:
  • R 3 is independently as defined for R-I a and R-" 3 or is oxo, and n is 1 or 2;
  • U is selected from CO and CH 2 ;
  • R5 is an optionally substituted bicyclic carbocyclic or heterocyclic ring system (B):
  • ⁇ 1 is C or N when part of an aromatic ring, or CR ⁇ 4 when part of a non-aromatic ring
  • ⁇ 2 is N, NR13, O, S(O) x , CO or CR ⁇ 4 when part of an aromatic or non-aromatic ring or may in addition be when part of a non aromatic ring
  • R14 and R ⁇ may together represent oxo; each R13 JS independently H; trifluoromethyl; (C-
  • This invention also provides a method of treatment of bacterial infections in mammals, particularly in man, which method comprises the administration to a mammal in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt and/or N-oxide thereof.
  • the invention also provides the use of a compound of formula (I), or a pharmaceutically acceptable salt and/or N-oxide thereof, in the manufacture of a medicament for use in the treatment of bacterial infections in mammals.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt and/or N-oxide thereof, and a pharmaceutically acceptable carrier.
  • Z 1 is CR 1c and Z 2 is CH;
  • Z 1 is CH and Z 2 is CR 1c ; Z 1 is CR 1c and Z 2 is N;or Z 1 is N and Z 2 is CR 1c .
  • R ⁇ a and R " " 3 are independently hydrogen, (C-
  • R ⁇ a and R-" 3 are hydrogen.
  • R ⁇ c is methyl.
  • R 2 is hydrogen.
  • R ⁇ is selected from hydrogen; (C-
  • n when A is (ia), n is 1. In a further aspect is in the 3- or 4-position. In a more particular aspect, A is (ia), n is 1 and s in the 3-position, and more particularly is cis to the group. In particular embodiments, A is a group (ia) in which n is 1 and is hydrogen or hydroxy. More particularly where A is 3-hydroxy- piperidin-4-yl the configuration is (3R,4S) or (3S,4R). Alternatively and more particularly where A is piperidin-4-yl the configuration is (3R,4S). In some embodiments, is hydrogen.
  • n is 1 , s in the 4- position and is methyl.
  • X is C is H and H or OH and more particularly OH is trans to R7.
  • W ⁇ is a bond.
  • R ⁇ is H.
  • W ⁇ is a bond 8 are both CH2 and R 7 is H.
  • U is CH2.
  • R ⁇ is an aromatic heterocyclic ring (B) having 8-11 ring atoms including 2-4 heteroatoms of which at least one is N or NR ⁇ in which, in particular embodiments, Y contains 2-3 heteroatoms, one of which is S and 1-2 are N, with one N bonded to
  • the heterocyclic ring (B) has ring (a) aromatic selected from optionally substituted benzo, pyrido, pyridazino, pyrimidino and pyrazino; and ring (b) non aromatic in which Y ⁇ has 3-5 atoms, more particularly 3 or 4 atoms, including at least one heteroatom, with O, S, CH2 or onded to here s hydrogen or other than hydrogen, and either NHCO bonded via N to or O, S, CH2 or NH bonded to X ⁇ .
  • the ring (a) contains aromatic nitrogen, and more particularly ring (a) is pyrido or pyrazino.
  • rings (B) include optionally substituted:
  • (a) is non aromatic (2S)-2,3-dihydro-1 H-indol-2-yl, (2S)-2,3-dihydro-benzo[1 ,4]dioxine-2-yl, 3-(R,S)-3,4- dihydro-2H-benzo[1 ,4]thiazin-3-yl, 3-(R)-2,3-dihydro-[1 ,4]dioxino[2,3-b]pyridin-3-yl, 3-(S)- 2,3-dihydro-[1 ,4]dioxino[2,3-b]pyridin-3-yl, 2,3-dihydro-benzo[1 ,4]dioxan-2-yl, 3- substituted-3H-quinazolin-4-one-2-yl,
  • R is an optional substituent (such as R 13 as defined herein) and ⁇ is the point of attachment.
  • s H if in ring (a) or in addition (C-
  • each R ⁇ j s independently selected from hydrogen, chloro, fluoro, hydroxy, methyl, methoxy, nitro and cyano. Still more particularly R ⁇ js independently selected from hydrogen, fluorine and nitro.
  • R 5 is: 2,3-dihydro-[1 ,4]dioxino[2,3-c]pyridin-7-yl; [1 ,3]oxathiolo[5,4-c]pyridin-6-yl; 2,3-dihydro[1 ,4]oxathiino[2,3-c]pyridin-7-yl; or 3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-yl.
  • Z 1 is CR 1c , R 1c is methyl, Z 2 is CH, R 1a and R 1b are hydrogen, A is (ia) wherein n is 1 and R 3 is hydrogen, R 2 is hydrogen, U is CH 2 and R 5 is any of the embodiments defined above, including individual embodiments.
  • Particular examples of compounds of the invention include:
  • alkyl When used herein, the terms “alkyl”, “alkenyl”, and “alkoxy” include groups having straight and branched chains.
  • .g) When a range of carbon numbers is used herein, e.g. "(C-
  • .g)alkyl includes alkyl groups having 1 , 2, 3, 4, 5 or 6 carbons, as well as (C-1.5), (C2-g), (C3-5), etc. alkyl.
  • .g)alkyl includes all straight and branched chain alkyl groups having from 1-6 carbons, e.g.
  • Halo or halogen includes fluoro, chloro, bromo and iodo.
  • Haloalkyl moieties include 1-3 halogen atoms.
  • substituents When a term includes "substituted alkyl," e.g. "(C-
  • substituent(s) may be present on any carbon atom of the alkyl group as permitted by chemistry.
  • the alkyl group is substituted in the 1 -position.
  • Some of the compounds of this invention may be crystallised or recrystallised from solvents such as aqueous and organic solvents. In such cases solvates may be formed.
  • This invention includes within its scope stoichiometric solvates including hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation.
  • phrases such as "a compound of formula (I) or a pharmaceutically acceptable salt and/or N-oxide thereof” are intended to encompass the compound of formula (I), an N-oxide of the compound of formula (I), a pharmaceutically acceptable salt of the compound of formula (I) or any pharmaceutically acceptable combination of these.
  • such compounds may be in the form of a solvate.
  • a compound of formula (I) or a pharmaceutically acceptable salt thereof may include a pharmaceutically acceptable salt of a compound of formula (I) that is further present as a solvate.
  • the compounds of formula (I) are intended for use in pharmaceutical compositions it will readily be understood that in particular embodiments they are provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and particularly at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions; these less pure preparations of the compounds should contain at least 1%, more suitably at least 5% and more particularly from 10% of a compound of the formula (I) or pharmaceutically acceptable salt and/or N-oxide thereof.
  • Particular compounds according to the invention include those mentioned in the examples and their pharmaceutically acceptable salts and/or N-oxides.
  • Pharmaceutically acceptable salts of the above-mentioned compounds of formula (I) include the acid addition or quaternary ammonium salts, for example their salts with mineral acids e.g. hydrochloric, hydrobromic, sulphuric, nitric or phosphoric acids, or organic acids, e.g. acetic, fumaric, succinic, maleic, citric, benzoic, p-toluenesulphonic, methanesulphonic, naphthalenesulphonic acid or tartaric acids.
  • Compounds of formula (I) may also be prepared as the N-oxide. The invention extends to all such derivatives.
  • Certain of the compounds of formula (I) may exist in the form of optical isomers, e.g.
  • the invention includes all such forms, in particular the pure isomeric forms.
  • the invention includes enantiomers and diastereoisomers at the attachment point of NR ⁇ and R3.
  • the different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.
  • the invention also includes compounds of formula I in any polymorphic forms.
  • L is an epoxide Or where and are both attached to the same carbon atom on A, Q is H and is together form ethylenedioxy or oxo, is or a group convertible thereto and is or a group convertible thereto, and A U and , are as defined in formula (I), followed by cyclisation and oxidation, to give a compound of formula (NIA):
  • Conversion to the epoxide (5) can be effected in a number of ways. Reaction with epichlorohydrin under basic conditions affords racemic epoxide. Reaction with (commercially available) R or S-glycidyl nosylate ((2R)- or (2S)-2-oxiranylmethyl 3- nitrobenzenesulfonate) or (2R)- or (2S)-2-oxiranylmethyl 4-methylbenzenesulfonate, with base, e.g. sodium hydride or potassium t-butoxide, gives the corresponding chiral epoxides. Alternatively, allylation with allyl bromide under basic conditions affords the corresponding N-allyl material which can be epoxidised under standard achiral or chiral conditions to give the corresponding achiral or chiral epoxides.
  • Oxidation to (9) may be carried out by oxidation of (8) with 2,3-dichloro-5,6-dicyano-1 ,4-benzoquinone (DDQ).
  • epoxide (5) may be prepared from (2) by first introducing a suitable epoxide precursor group (-CH2-CHOH-CH2OH, protected as a cyclic ester) before carrying out the steps (b) and (c).
  • L in (NIA) is not necessarily the same as L in (NA).
  • L in (NA) is used to effect cyclization to the tricyclic (NIA).
  • the resulting “L” can be modified to attach the remaining portion of compound. This applies in analogous manner to the Schemes 2-4.
  • L may be a hydroxy group which can be oxidised to the aldehyde by conventional means such as 1 ,1 ,1-tris-(acetyloxy)-1 ,1-dihydro-1 ,2-benziodooxol-3-(1 H)-one for reductive alkylation with HA-N(R20)R2' unc
  • - conventional conditions see for examples Smith, M. B.; March, J. M. Advanced Organic Chemistry, Wiley-lnterscience 2001 ).
  • L may be bromo which can be alkylated with HA-N(R20)R2' unc
  • the ketal may be converted to the ketone (Q-I and Q2 together form oxo) by conventional acid hydrolysis treatment with e.g. aqueous HCI or trifluoroacetic acid and the subsequent conversion to NR2UR5 by conventional reductive alkylation with amine NHR2 R20 (see f O r example Nudelman, A., et al, Tetrahedron 60 (2004) 1731-1748) and subsequent conversion to the required substituted amine, or directly with NHR2UR5, such as with sodium triacetoxyborohydride in dichloromethane/methanol.
  • R20 and R2' is an N-protecting group, such as such as t- butoxycarbonyl, benzyloxycarbonyl or 9-fluorenylmethyloxycarbonyl.
  • N-protecting group such as such as t- butoxycarbonyl, benzyloxycarbonyl or 9-fluorenylmethyloxycarbonyl.
  • This may be removed by several methods well known to those skilled in the art (for examples see "Protective Groups in Organic Synthesis, T.W. Greene and P. G. M. Wuts, Wiley- Interscience, 1999), for example conventional acid hydrolysis with, for example trifluoroacetic acid or hydrochloric acid.
  • the invention further provides compounds of formula (NIA) in which L is -A-N(R 20 )R 2 ' and R 20 is hydrogen.
  • the free amine of formula (NIA) in which R 2 O is hydrogen may be converted to NR 2 URS by conventional means such as amide formation with an acyl derivative
  • R ⁇ COW for compounds where U is CO or, where U is CH2, by alkylation with an alkyl halide R ⁇ Ch ⁇ -halide in the presence of base, acylation/reduction with an acyl derivative
  • R ⁇ COW or reductive alkylation with an aldehyde R ⁇ CHO under conventional conditions see for examples Smith, M. B.; March, J. M. Advanced Organic Chemistry, Wiley- Interscience 2001 ).
  • the appropriate reagents containing the required R ⁇ group are known compounds or may be prepared analogously to known compounds, see for example WO02/08224, WO02/50061 , WO02/56882, WO02/96907, WO2003087098, WO2003010138, WO2003064421 , WO2003064431 , WO2004002992, WO2004002490, WO2004014361 , WO2004041210,WO2004096982, WO2002050036, WO2004058144, WO2004087145, WO06002047, WO06014580, WO06010040, WO06017326,
  • R ⁇ contains an NH group
  • this may be protected with a suitable N- protecting group such as t-butoxycarbonyl, benzyloxycarbonyl or 9- fluorenylmethyloxycarbonyl during the coupling of the R ⁇ derivative with the free amine of formula (NB).
  • the protecting group may be removed by conventional methods, such as by treatment with trifluoroacetic acid.
  • L is a leaving group or where and are both attached to the same carbon atom on A, Q ⁇ is H and Q 2 is N(R 2 ⁇ )R 2 ' O r Q1 and Q 2 together form ethylenedioxy or oxo , or a group convertible thereto and R 2 is R 2 or a group convertible thereto, and A, are as defined in formula (I), followed by cyclisation and oxidation, to give a compound of formula formula (1MB):
  • the reaction of (NB) and subsequent transformations to form (1MB) are carried out as for the preparation of compounds of formula (NIA).
  • the invention further provides compounds of formula (1MB) in which L is -A- is hydrogen.
  • the commercially available 2-amino-4-methyl-6-methoxypyridine (10) may be acylated with pivaloyl chloride and an amine base such as triethylamine to give the acylated compound (11 ).
  • a amine base such as triethylamine
  • Directed lithiation followed by lithium-halogen exchange with 1 ,2-dibromoethane gives brominated compound (12) (see for example Cottineau, et al, Tetrahedron 63 (2007) 10354-10362).
  • L is a leaving group o where and are both attached to the same carbon atom on A is H and is O and ogether form ethylenedioxy or oxo, js U or a group convertible thereto and R ⁇ is R ⁇ or a group convertible thereto, and A, U and ⁇ are as defined in formula (I), followed by cyclisation and oxidation to give a compound of formula (NIC):
  • the invention further provides compounds of formula (NIC) in which L is -A-
  • N(R 20 )R 2 ' and R 20 is hydrogen.
  • the invention further provides compounds of formula (NID) in which L is -A- N(R20)R2' and R 20 is hydrogen.
  • R ⁇ a , R-" 3 , R ⁇ , A and R ⁇ are conventional.
  • suitable conventional hydroxy protecting groups which may be removed without disrupting the remainder of the molecule include acyl and alkylsilyl groups. N-protecting groups are removed by conventional methods.
  • R ⁇ a and R-" 3 groups may be carried out conventionally, on compounds of formula (I).
  • R ⁇ a or R " " 3 methoxy is convertible to R ⁇ a or
  • R “ 3 hydroxy by treatment with lithium and diphenylphosphine (general method described in Ireland et al, J. Amer. Chem. Soc, 1973, 7829) or HBr. Alkylation of the hydroxy group with a suitable alkyl derivative bearing a leaving group such as halide, yields R ⁇ a or R “ " 3 substituted alkoxy. R ⁇ a or R “ “ 3 halo such as bromo may be converted to cyano by treatment with copper (I) cyanide in N,N-dimethylformamide. R ⁇ a or R “ “ 3 carboxy may be obtained by conventional hydrolysis of R ⁇ a or R-" 3 cyano, and the carboxy converted to hydroxymethyl by conventional reduction.
  • HA-N(R20)R2' are known compounds or may be prepared analogously to known compounds, see for example WO2004/035569, WO2004/089947, WO02/08224, WO02/50061 , WO02/56882, WO02/96907, WO2003087098, WO2003010138, WO2003064421 , WO2003064431 , WO2004002992, WO2004002490, WO2004014361 , WO2004041210.WO2004096982, WO2002050036, WO2004058144, WO2004087145, WO2003082835, WO2002026723, WO06002047 and WO06014580, WO06134378, WO06137485, WO07016610, WO07081597, WO07071936, WO071 15947, WO07118130, WO07122258, WO08006648, WO0800
  • compositions of the invention may be formulated for administration by any route and include those in a form adapted for oral, topical or parenteral use and may be used for the treatment of bacterial infection in mammals including humans.
  • compositions may be in the form of tablets, capsules, powders, granules, lozenges, suppositories, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions.
  • topical formulations of the present invention may be presented as, for instance, ointments, creams or lotions, eye ointments and eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration, and emollients in ointments and creams.
  • the formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions.
  • suitable conventional carriers such as cream or ointment bases and ethanol or oleyl alcohol for lotions.
  • Such carriers may be present as from about 1 % up to about 98% of the formulation. More usually they will form up to about 80% of the formulation.
  • Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives, such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and, if desired, conventional flavouring or colouring agents.
  • suspending agents for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats
  • emulsifying agents for example lecithin, sorbitan monooleate, or
  • Suppositories will contain conventional suppository bases, e.g. cocoa-butter or other glyceride.
  • fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred.
  • the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • agents such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • the dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use.
  • Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration.
  • the compound can be sterilised by exposure to ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • the compositions may contain from 0.1 % by weight, preferably from 10-60% by weight, of the active material (e.g. compound of formula (I) or pharmaceutically acceptable salt and/or N-oxide thereof), depending on the method of administration.
  • compositions comprise dosage units
  • each unit will preferably contain from 50-1000 mg of the active ingredient.
  • the dosage as employed for adult human treatment will preferably range from 100 to 3000 mg per day, for instance 1500 mg per day depending on the route and frequency of administration. In some embodiments from about 1.5 to about 50 mg active/kg patient body weight is administered per day. Suitably the dosage is from 5 to 30 mg/kg per day.
  • the compound of formula (I) may be the sole therapeutic agent in the compositions of the invention or a combination with other antibacterials including antitubercular compounds. If the other antibacterial is a ⁇ -lactam then a ⁇ -lactamase inhibitor may also be employed.
  • Compounds of formula (I) may be used to inhibit the growth of one or more of a wide range of organisms including both Gram-negative and Gram-positive organisms, including, for example, one or more of: Hemophilus influenzae, Klebsiella pneumoniae,
  • Neisseria gonorrhoeae Neisseria gonorrhoeae
  • Neisseria meningitides Moraxella catarrhalis
  • Some compounds of formula (I) may be active against more than one organism.
  • compounds of the invention have activity against one or more of:
  • Mycobacterium tuberculosis Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium.
  • Compounds of formula (I) may therefore be used in the treatment of bacterial infections caused by a wide range of organisms including both Gram-negative and Gram-positive organisms, including the above-listed organisms, such as upper and/or lower respiratory tract infections, skin and soft tissue infections and/or urinary tract infections, including for example tuberculosis caused by Mycobacterium tuberculosis.
  • Antibacterial activity may be determined by the methods described herein.
  • LCMS/LC-MS Liquid chromatography mass spectroscopy
  • TFA trifluoroacetic acid
  • THF refers to tetrahydrofuran
  • Pd/C palladium on carbon catalyst
  • DCM dichloromethane
  • MeOH refers to methanol
  • DMF dimethylformamide
  • EtOAc refers to ethylacetate
  • DDQ 2,3-dichloro-5,6-dicyano-1 ,4-benzoquinone
  • NaBH(OAc) 3 refers to sodium triacetoxyborohydride
  • Pd 2 (dba) 3 refers to tris(dibenzylideneacetone)dipalladium (0).
  • AD mix alpha is prepared by mixing potassium osmate (K 2 OsO 4 .2H 2 O) (0.52g), (3a,9R,3'"a,4'"b,9'”R)-9,9'-[1 ,4-phthalazinediylbis(oxy)]bis[6'-(methyloxy)-10, 11 - dihydrocinchonan] [(DHQ) 2 PHAL] (5.52g), then adding potassium ferricyanide
  • AD mix beta is the corresponding mixture prepared with (9S,9'"S)-9,9'- [1 ,4-phthalazinediylbis(oxy)]bis[6'-(methyloxy)-10, 11-dihydrocinchonan] [(DHQD) 2 PHAL].
  • AD mix alpha/beta is referred to, this is a 1 :1 mixture of the alpha and beta mix.
  • Celite® is a filter aid composed of acid-washed diatomaceous silica, and is a trademark of Manville Corp., Denver, Colorado.
  • SCX Cartridge is an ion exchange column containing strong cation exchange resin ( benzene sulfonic acid) supplied by Varian, USA.
  • Chiralpak IA and Chiralpak AS-H are polysaccharide based chiral HPLC columns
  • Chiralpak AS-H column comprise amylose tris [(S)- alpha- methylbenzylcarbamate) coated onto 5 ⁇ m silica.
  • Chiralpak IA column comprise silica for preparative column (5 ⁇ m particle size, 21 mm ID x 250mm L ) immobilized with Amylose tris (3,5-dimethylphenylcarbamate).
  • Chiralpak AD and AD-H columns comprise silica for preparative columns (5 ⁇ m particle size AD-H and 10 ⁇ m particle size AD, 21 mm ID x
  • references to preparations carried out in a similar manner to, or by the general method of, other preparations may encompass variations in routine parameters such as time, temperature, workup conditions, minor changes in reagent amounts etc.
  • Reactions involving metal hydrides including lithium hydride, lithium aluminium hydride, di-isobutylaluminium hydride, sodium hydride, sodium borohydride and sodium triacetoxyborohydride are carried out under argon or other inert gas.
  • Example 1 (1/?)-1-( ⁇ 4-[(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1- piperidinyl ⁇ methyl)-6-methyl-1 ,2-dihydro-4H,9H-imidazo[1 ,2,3-/y]-1 ,8-naphthyridine- 4,9-dione hydrochloride
  • reaction mixture was heated at reflux (the colour of the reaction changed from burgundy to yellow). After 2h there was still 12% of product so the reaction was stirred at reflux overnight. There was still some starting material (9%) present but reaction was getting messy so the solvent was removed and water (25OmL) was added and extracted with diethyl ether (3x250ml_).
  • reaction mixture was treated with aqueous K 2 CO 3 (5%, 10OmL) and with DCM (100ml); the organic layer was separated and the aqueous was extracted with DCM (2 x 100ml). The combined organic layers were then dried (NaSO 4 ), filtered and evaporated to give 550mg of crude product as an orange solid.
  • the minimum inhibitory concentration (MIC) was determined as the lowest concentration of compound that inhibited visible growth. A mirror reader was used to assist in determining the MIC endpoint. Compounds were evaluated against Gram-positive organisms, including
  • Staphylococcus aureus Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecalis and Enterococcus faecium.
  • Each of the listed Examples, as identified in the present application was tested in the exemplified salt form.
  • the tested Examples had a MIC ⁇ 2 ⁇ g/ml against a strain of at least one of the organisms listed above.
  • MIC minimum inhibitory concentration
  • Isoniazid starting at 160 ⁇ gmT ' was prepared and 5 ⁇ l of this control curve was added to 95 ⁇ l of Middlebrook 7H9 (Difco catalogue Ref. 271310) + ADC medium (Becton Dickinson Catalogue Ref. 211887). (Row 1 1 , lines A-H). Five ⁇ l of neat DMSO were added to row 12 (growth and Blank controls).
  • the inoculum was standardised to approximately 1x10 7 cfu/ml and diluted 1 in 100 in Middlebrook 7H9+ADC medium and 0.025% Tween 80 (Sigma P4780), to produce the final inoculum of H37Rv strain (ATCC25618).
  • One hundred ⁇ l of this inoculum was added to the entire plate but G-12 and H-12 wells (Blank controls). All plates were placed in a sealed box to prevent drying out of the peripheral wells and they were incubated at 37 0 C without shaking for six days.
  • a resazurin solution was prepared by dissolving one tablet of resazurin (Resazurin Tablets for Milk Testing; Ref 330884Y VWR International Ltd) in 30 ml sterile PBS (phosphate buffered saline). 25 ⁇ l of this solution was added to each well. Fluorescence was measured (Spectramax M5
  • Examples 1-4 were tested in the Mycobacterium tuberculosis H37Rv inhibition assay. Examples 1 , 2 and 4 showed an MIC value of lower than 2.0 ⁇ g/ml. Example 3 showed an MIC value of > 2.5 ⁇ g/ml.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Tricyclic nitrogen containing compounds (I) and their use as antibacterials.

Description

TRICYCLIC NITROGEN COMPOUNDS USED AS ANTIBACTERIALS
This invention relates to novel compounds, compositions containing them and their use as antibacterials. WO02/08224, WO02/50061 , WO02/56882, WO02/96907, WO2003087098,
WO2003010138, WO2003064421 , WO2003064431 , WO2004002992, WO2004002490, WO2004014361 , WO2004041210,WO2004096982, WO2002050036, WO2004058144, WO2004087145, WO2006002047, WO2006014580, WO2006010040, WO2006017326, WO2006012396, WO2006017468, WO2006020561 , WO2006081 179, WO2006081264, WO2006081289, WO2006081178, WO2006081182, WO01/25227, WO02/40474, WO02/07572, WO2004024712, WO2004024713, WO2004035569, WO2004087647, WO2004089947, WO2005016916, WO2005097781 , WO2006010831 , WO2006021448, WO2006032466, WO2006038172, WO2006046552, WO06099884, WO06126171 , WO06137485, WO06105289, WO06125974, WO06134378, WO07016610, WO07081597, WO07071936, WO07115947, WO07118130, WO07122258,
WO08006648, WO08003690 and WO08009700 disclose quinoline, naphthyridine, morpholine, cyclohexane, piperidine and piperazine derivatives having antibacterial activity. WO2004104000 discloses tricyclic condensed ring compounds capable of selectively acting on cannabinoid receptors. WO2003048081 , WO2003048158 and US2003232804 disclose glycinamides as Factor Xa inhibitors.
This invention provides a compound of formula (I) or a pharmaceutically acceptable salt and/or N-oxide thereof:
wherein:
one of Z1 and Z2 is CR1c and the other is CH or N;
R^a and R-"3 are independently selected from hydrogen; halogen; cyano; (C-|.g)alkyl; (C-|.g)alkylthio; trifluoromethyl; trifluoromethoxy; carboxy; (C-|.g)alkoxy; hydroxy; hydroxy optionally substituted with (C-|.g)alkoxy-substituted(C-|.g)alkyl; (C-|_g)alkoxy- substituted(C-|.g)alkyl; hydroxy(C-|.g)alkyl; an amino group optionally N-substituted by one or two (C-|.g)alkyl, formyl, (C-|.g)alkylcarbonyl or (C-|.g)alkylsulphonyl groups; and aminocarbonyl wherein the amino group is optionally substituted by one or two (C-|. 4)alkyl;
provided that and are H whe N, respectively;
R1 c is (C-|.g)alkyl;
R2 is hydrogen, (C-|_4)alkyl, or together with R^ forms Y as defined below;
A is a group (i) selected from:
(ia) or (ib)
in which:
R3 is independently as defined for R-I a and R-"3 or is oxo, and n is 1 or 2;
or A is a group
(ϋ) wherein: represents a bond between W3 and N; one R4 is independently as defined for R^ a and R""3 and the remainder and R8 are hydrogen, or one R4 and R8 are together oxo and the remainder are hydrogen; R6 is hydrogen, (C-|.g)alkyl, or together with R2 forms Y; R7 is hydrogen; halogen; (C-|.g)alkoxy; hydroxy; or (C-|.g)alkyl;
Y is CR4R8CH2; CH2CR4R8; (C=O); CR4R8; CR4R8(C=O); or (C=O)CR4R8 where R4 and R8 are independently as defined above; or when X is CR4R8, R8 and R7 together represent a bond;
U is selected from CO and CH2; and
R5 is an optionally substituted bicyclic carbocyclic or heterocyclic ring system (B):
containing up to four heteroatoms in each ring in which at least one of rings (a)and (b) is aromatic; χ1 is C or N when part of an aromatic ring, or CR^4 when part of a non-aromatic ring; χ2 is N, NR13, O, S(O)x, CO or CR^4 when part of an aromatic or non-aromatic ring or may in addition be when part of a non aromatic ring; and are independently N or C; is a 0 to 4 atom linker group each atom of which is independently selected from N, , O, S(O)x, CO an when part of an aromatic or non-aromatic ring or may additionally be when part of a non aromatic ring; is a 2 to 6 atom linker group, each atom of being independently selected from when part of an aromatic or non-aromatic ring or may additionally be when part of a non aromatic ring; each of and is independently selected from: H; (C-|_4)alkylthio; halo; carboxy (C-|_4)alkyl; hydroxy; hydroxy(C-|_4)alkyl; (C-|_4)alkoxy; nitro; cyano; carboxy; amino or aminocarbonyl optionally mono- or di-substituted by (C-|_4)alkyl; or
R14 and R^ may together represent oxo; each R13 JS independently H; trifluoromethyl; (C-|_4)alkyl optionally substituted by hydroxy, (C-|.g)alkoxy, (C-|.g)alkylthio, halo or trifluoromethyl; (C2-4)alkenyl; (C-|.
4)alkoxycarbonyl; (C-|_4)alkylcarbonyl; (C-|.g)alkylsulphonyl; aminocarbonyl wherein the amino group is optionally mono or disubstituted by (C-|_4)alkyl; and each x is independently 0, 1 or 2.
This invention also provides a method of treatment of bacterial infections in mammals, particularly in man, which method comprises the administration to a mammal in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt and/or N-oxide thereof.
The invention also provides the use of a compound of formula (I), or a pharmaceutically acceptable salt and/or N-oxide thereof, in the manufacture of a medicament for use in the treatment of bacterial infections in mammals.
The invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt and/or N-oxide thereof, and a pharmaceutically acceptable carrier. In particular aspects: Z1 is CR1c and Z2 is CH;
Z1 is CH and Z2 is CR1c; Z1 is CR1c and Z2 is N;or Z1 is N and Z2 is CR1c.
In a particular aspects R^ a and R""3 are independently hydrogen, (C-|_4)alkoxy, (C-|_4)alkylthio, (C-|_4)alkyl, cyano, carboxy, hydroxymethyl or halogen; more particularly hydrogen, methoxy, methyl, cyano, or halogen.
In particular embodiments R^ a and R-"3 are hydrogen. In particular embodiments R^ c is methyl. In a particular aspect R2 is hydrogen. In particular embodiments R^ is selected from hydrogen; (C-|.g)alkoxy; hydroxy; hydroxy optionally substituted with (C-|.g)alkoxy-substituted(C-|.g)alkyl; optionally substituted amino; halogen; (C-1.4) alkyl; 1-hydroxy-(C-|_4) alkyl; and optionally substituted aminocarbonyl. In more particular embodiments, s selected from hydrogen; CONH2; 1-hydroxyalkyl (e.g lkoxy (e.g. methoxy); hydroxy; hydroxy optionally substituted with (C-|.g)alkoxy-substituted(C-|.g)alkyl; optionally substituted amino; and halogen (e.g. fluoro). Most particularly is hydrogen, hydroxy or fluoro.
In a particular aspect, when A is (ia), n is 1. In a further aspect is in the 3- or 4-position. In a more particular aspect, A is (ia), n is 1 and s in the 3-position, and more particularly is cis to the group. In particular embodiments, A is a group (ia) in which n is 1 and is hydrogen or hydroxy. More particularly where A is 3-hydroxy- piperidin-4-yl the configuration is (3R,4S) or (3S,4R). Alternatively and more particularly where A is piperidin-4-yl the configuration is (3R,4S). In some embodiments, is hydrogen.
In an alternative more particular aspect, when A is (ia), n is 1 , s in the 4- position and is methyl. In a particular aspect, when A is (ii), X is C is H and H or OH and more particularly OH is trans to R7. In a further aspect W^ is a bond. In another aspect R^ is H. In an additional aspect W^ is a bond 8 are both CH2 and R7 is H. Where A is 4-hydroxypyrrolidin-3-ylmethyl, in a particular aspect the configuration is (3S,4S). Where A is pyrrolidin-3-ylmethyl, in a particular aspect the configuration is 3S.
In a particular aspect, when are each CH2-
In certain embodiments U is CH2.
In certain embodiments R^ is an aromatic heterocyclic ring (B) having 8-11 ring atoms including 2-4 heteroatoms of which at least one is N or NR^ in which, in particular embodiments, Y contains 2-3 heteroatoms, one of which is S and 1-2 are N, with one N bonded to
In alternative embodiments the heterocyclic ring (B) has ring (a) aromatic selected from optionally substituted benzo, pyrido, pyridazino, pyrimidino and pyrazino; and ring (b) non aromatic in which Y^ has 3-5 atoms, more particularly 3 or 4 atoms, including at least one heteroatom, with O, S, CH2 or onded to here s hydrogen or other than hydrogen, and either NHCO bonded via N to or O, S, CH2 or NH bonded to X^. In a particular aspect the ring (a) contains aromatic nitrogen, and more particularly ring (a) is pyrido or pyrazino. Examples of rings (B) include optionally substituted:
(a) and (b) aromatic
1 H-pyrrolo[2,3-b]-pyridin-2-yl, 1 H-pyrrolo[3,2-b]-pyridin-2-yl, 3H-imidazo[4,5-b]-pyrid-2-yl, 3H-quinazolin-4-one-2-yl, benzimidazol-2-yl, benzo[1 ,2,3]-thiadiazol-5-yl, benzo[1 ,2,5]- oxadiazol-5-yl, benzofur-2-yl, benzothiazol-2-yl, benzo[b]thiophen-2-yl, benzoxazol-2-yl, chromen-4-one-3-yl, imidazo[1 ,2-a]pyridin-2-yl, imidazo-[1 ,2-a]-pyrimidin-2-yl, indol-2-yl, indol-6-yl, isoquinolin-3-yl, [1 ,8]-naphthyridine-3-yl, oxazolo[4,5-b]-pyridin-2-yl, quinolin- 2-yl, quinolin-3-yl, quinoxalin-2-yl, naphthalen-2-yl, 1 ,3-dioxo-isoindol-2yl, 1 H- benzotriazol-5-yl, 1 H-indol-5-yl, 3H-benzooxazol-2-one-6-yl, 3H-benzooxazol-2-thione-6- yl, 3H-benzothiazol-2-one-5-yl, 3H-quinazolin-4-one-6-yl, pyrido[1 ,2-a]pyrimidin-4-one-3- yl (4-oxo-4H-pyrido[1 ,2-a]pyrimidin-3-yl), benzo[1 ,2,3]thiadiazol-6-yl, benzo[1 ,2,5]thiadiazol-5-yl, benzo[1 ,4]oxazin-2-one-3-yl, benzothiazol-5-yl, benzothiazol- 6-yl, cinnolin-3-yl, imidazo[1 ,2-b]pyridazin-2-yl, pyrazolo[1 ,5-a]pyrazin-2-yl, pyrazolo[1 ,5- a]pyridin-2-yl, pyrazolo[1 ,5-a]pyrimidin-6-yl, pyrazolo[5,1-c][1 ,2,4]triazin-3-yl, pyrido[1 ,2- a]pyrimdin-4-one-2-yl (4-oxo-4H-pyrido[1 ,2-a]pyrimidin-2-yl), quinazolin-2-yl, quinoxalin- 6-yl, thiazolo[3,2-a]pyrimidin-5-one-7-yl, thiazolo[5,4-b]pyridin-2-yl, thieno[3,2-b]pyridin-6- yl, thiazolo[5,4-b]pyridin-6-yl, thiazolo[4,5-b]pyridin-5-yl, [1 ,2,3]thiadiazolo[5,4-b]pyridin-6- yl, 2H-isoquinolin-1-one-3-yl (1-oxo-1 ,2-dihydro-isoquinolin-3-yl), [1 ,2,3]thiadiazolo[5,4- b]pyridine-6-yl
in which → is the point of attachment
(a) is non aromatic (2S)-2,3-dihydro-1 H-indol-2-yl, (2S)-2,3-dihydro-benzo[1 ,4]dioxine-2-yl, 3-(R,S)-3,4- dihydro-2H-benzo[1 ,4]thiazin-3-yl, 3-(R)-2,3-dihydro-[1 ,4]dioxino[2,3-b]pyridin-3-yl, 3-(S)- 2,3-dihydro-[1 ,4]dioxino[2,3-b]pyridin-3-yl, 2,3-dihydro-benzo[1 ,4]dioxan-2-yl, 3- substituted-3H-quinazolin-4-one-2-yl,
in which → is the point of attachment
(b) is non aromatic
1 ,1 ,3-trioxo-1 ,2,3,4-tetrahydro1 /6-benzo[1 ,4] thiazin-6-yl, benzo[1 ,3]dioxol-5-yl, 2,3- dihydro-benzo[1 ,4]dioxin-6-yl, 3-substituted-3H-benzooxazol-2-one-6-yl, 3-substituted- 3H-benzooxazole-2-thione-6-yl, 3-substituted-3H-benzothiazol-2-one-6-yl, 4H- benzo[1 ,4]oxazin-3-one-6-yl (3-oxo-3,4-dihydro-2H-benzo[1 ,4]oxazin-6-yl), 4H- benzo[1 ,4]thiazin-3-one-6-yl (3-oxo-3,4-dihydro-2H-benzo[1 ,4]thiazin-6-yl), 4H- benzo[1 ,4]oxazin-3-one-7-yl, 4-oxo-2,3,4,5-tetrahydro-benzo[b][1 ,4]thiazepine-7-yl, 5- oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidin-6-yl, 1 H-pyrido[2,3-b][1 ,4]thiazin-2-one-7-yl (2-0X0-2, 3-d ihydro-1 H-pyrido[2,3-b]thiazin-7-yl), 2,3-dihydro-1 H-pyrido[2,3-b][1 ,4]thiazin- 7-yl, 2-0X0-2, 3-d ihydro-1 H-pyrido[3,4-b]thiazin-7-yl, 2,3-dihydro-[1 ,4]dioxino[2,3- b]pyridin-6-yl, 2,3-dihydro-[1 ,4]dioxino[2,3-c]pyridin-7-yl, 2,3-dihydro-[1 ,4]dioxino[2,3- b]pyridin-7-yl, 3,4-dihydro-2H-benzo[1 ,4]oxazin-6-yl, 3,4-dihydro-2H-benzo[1 ,4]thiazin-6- yl, 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1 ,4]oxazin-6-yl, 3,4-dihydro-2H-pyrido[3,2- b][1 ,4]thiazin-6-yl, 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1 ,4]thiazin-6-yl, 3,4-dihydro-1 H- quinolin-2-one-7-yl, 3,4-dihydro-1 H-quinoxalin-2-one-7-yl, 6,7-dihydro-4H-pyrazolo[1 ,5- a]pyrimidin-5-one-2-yl, 5,6,7,8-tetrahydro-[1 ,8]naphthyridin-2-yl (1 ,2,3,4-tetrahydro- [1 ,8]naphthyridin-7-yl), 2-oxo-3,4-dihydro-1 H-[1 ,8]naphthyridin-6-yl, 6-oxo-6,7-dihydro- 5/-/-pyridazino[3,4-b][1 ,4]thiazin-3-yl (6-oxo-6,7-dihydro-5H-8-thia-1 ,2,5-triaza- naphthalen-3-yl), 2-oxo-2,3-dihydro-1 H-pyrido[3,4-b][1 ,4]oxazin-7-yl, 2-oxo-2,3-dihydro- 1 H-pyrido[2,3-b][1 ,4]oxazin-7-yl, 6,7-dihydro-[1 ,4]dioxino[2,3-d]pyrimidin-2-yl, [1 ,3]oxathiolo[5,4-c]pyridin-6-yl, 3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-yl, 2,3- dihydro[1 ,4]oxathiino[2,3-c]pyridin-7-yl, 6,7-dihydro[1 ,4]dioxino[2,3-c]pyridazin-3-yl, 5,6,7,8-tetrahydroisoquinolin-3-yl, 6,7-dihydro-5/-/-cyclopenta[c]pyridin-3-yl, 1 ,3- dihydrofuro[3,4-c]pyridin-6-yl, 3,4-dihydro-2/-/-[1 ,4]oxathiepino[2,3-c]pyridin-8-yl, [1 ,3]oxathiolo[4,5-c]pyridin-6-yl, 6,7-dihydro[1 ,4]oxathiino[2,3-c]pyridazin-3-yl, 6,7- dihydro-5H-pyrano[2,3-c]pyridazin-3-yl, 5,6-dihydrofuro[2,3-c]pyridazin-3-yl, 2,3- dihydrofuro[2,3-c]pyridin-5-yl, 2-substituted 1 /-/-pyrimido[5,4-b][1 ,4]oxazin-7(6/-/)-one, 2- substituted 5,6-dihydropyrido[2,3-c/]pyrimidin-7(1/-/)-one, 7- substituted 2H-chromen-2- one, 7-substituted 2/-/-pyrano[2,3-b]pyridin-2-one, 2-substituted 6,7-dihydro-5H- pyrano[2,3-c/]pyrimidine, 8-substitited 2/-/-pyrido[1 ,2-a]pyrimidin-2-one, 2,3-dihydro-1- benzofuran-5-yl, 1 H-pyrimido[5,4-b][1 ,4]thiazin-7(6H)-one-2-yl, 3,4-dihydro-2H-chromen- 7-yl, 2,3-dihydro-1-benzofuran-6-yl, 3,4-dihydro-2H-chromen-6-yl, 3,4-dihydro-2H- pyrido[3,2-b][1 ,4]oxazine-6-yl, 3,4-dihydro-2H-pyrido [3,2-b][1 ,4]thiazine-6-yl, 6,7- dihydro-5H-thieno[3,2-b]pyran-2-yl, 2,3,4,5-tetrahydro-1 ,5-benzothiazepine-7-yl.
where R is an optional substituent (such as R13 as defined herein) and → is the point of attachment. In some embodiments s H if in ring (a) or in addition (C-|_4)alkyl such as methyl or isopropyl when in ring (b). More particularly, in ring (b) R^ 3 is H when s bonded to χ3 and (C-|_4)alkyl when NR13 js bonded to X^.
In further embodiments and are independently selected from hydrogen, halo, hydroxy, (C-1.4) alkyl, ( nitro and cyano. More particularly s hydrogen.
More particularly each R^ js independently selected from hydrogen, chloro, fluoro, hydroxy, methyl, methoxy, nitro and cyano. Still more particularly R^ js independently selected from hydrogen, fluorine and nitro.
Most particularly and are each H. Particular groups nclude:
[1 ,2,3]thiadiazolo[5,4-b]pyridin-6-yl
1 H-pyrrolo[2,3-b]pyridin-2-yl
2,3-dihydro-[1 ,4]dioxino[2,3-b]pyridin-6-yl
2,3-dihydro-[1 ,4]dioxino[2,3-b]pyridin-7-yl 2,3-dihydro-[1 ,4]dioxino[2,3-c]pyridin-7-yl
2,3-dihydro-benzo[1 ,4]dioxin-6-yl
2-0X0-2, 3-d ihydro-1 H-pyrido[2,3-b][1 ,4]oxazin-7-yl
2-0X0-2, 3-d ihydro-1 H-pyrido[2,3-b][1 ,4]thiazin-7-yl
3,4-dihydro-2H-benzo[1 ,4]oxazin-6-yl 3-methyl-2-oxo-2,3-dihydro-benzooxazol-6-yl
3-0X0-3, 4-dihydro-2H-benzo[1 ,4]oxazin-6-yl S-oxo-S^-dihydro^H-pyridoβ^-bHMJoxazin-θ-yl
3-oxo-3,4-dihydro-2H-benzo[1 ,4]thiazin-6-yl (4H-benzo[1 ,4] thiazin-3-one-6-yl)
4-oxo-4H-pyrido[1 ,2-a]pyrimidin-2-yl
6-nitro-benzo[1 ,3]dioxol-5-yl 7-fluoro-3-oxo-3,4-dihydro-2H-benzo[1 ,4] oxazin-6-yl
8-hydroxy-1 -oxo-1 ,2-dihydro-isoquinolin-3-yl
8-hydroxyquinolin-2-yl benzo[1 ,2,3]thiadiazol-5-yl benzo[1 ,2,5]thiadiazol-5-yl benzothiazol-5-yl thiazolo-[5,4-b]pyridin-6-yl
3-oxo-3,4-dihydro-2H-pyrido[3,2-d][1 ,4]thiazin-6-yl
7-chloro-3-oxo-3!4-dihydro-2H-pyrido[3!2-jb][1 ,4]thiazin-6-yl
7-chloro-3-oxo-3,4-dihydro-2H-pyrido[3,2-d][1 ,4]oxazin-6-yl 7-fluoro-3-oxo-3!4-dihydiO-2/-/-pyrido[3!2-jb][1 ,4]thiazin-6-yl
2-0X0-2, 3-d ihydro-1 H-pyrido[3,4-b][1 ,4]thiazin-7-yl
[1 ,3]oxathiolo[5,4-c]pyridin-6-yl
S^-dihydiO^H-pyrano^S-φyridin-e-yl
5-carbonitro-2,3-dihydro-1 ,4-benzodioxin-7-yl 2,3-dihydro[1 ,4]oxathiino[2,3-c]pyridin-7-yl
6,7-dihydro[1 ,4]dioxino[2,3-c]pyridazin-3-yl
5,6,7,8-tetrahydroisoquinolin-3-yl
6,7-dihydro-5/-/-cyclopenta[c]pyridin-3-yl
1 ,3-dihydrofuro[3,4-c]pyridin-6-yl 6-fluoro-2,3-dihydro-1 ,4-benzodioxin-7-yl
[1 ,3]oxathiolo[4,5-c]pyridine-6-yl
2,3-dihydro-1-benzofuran-5-yl
6,7-dihydro[1 ,4]oxathiino[2,3-c]pyridazin-3-yl 6,7-dihydro-5H-pyrano[2,3-c]pyridazin-3-yl
5,6-dihydrofuro[2,3-c]pyridazin-3-yl
2-substituted 1 H-pyrimido[5,4-b][1 ,4]oxazin-7(6H)-one
2-substituted 4-chloro-1 H-pyιϊmido[5,4-b][1 ,4]oxazin-7(6H)-one
2-substituted 5,6-dihydropyrido[2,3-d]pyrimidin-7(1 H)-one 2-substituted 4-chloro-5,6-dihydropyrido[2,3-d]pyrimidin-7(1 H)-one
2-substituted 4-methyl-5,6-dihydropyrido[2,3-d]pyrimidin-7(1 H)-one 2-substituted 4-methyloxy-5,6-dihydropyrido[2,3-d]pyrimidin-7(1 H)-one
7-substituted 2H-chromen-2-one
7-substituted 2/-/-pyrano[2,3-b]pyridin-2-one
4-chloro-6,7-dihydro-5/-/-pyrano[2,3-c/]pyrimidin-2-yl 8-substituted 2/-/-pyrido[1 ,2-a]pyrimidin-2-one
6,7-dihydro-5H-pyrano[2,3-c/]pyrimidin-2-yl)
5-chloro-1-benzothiophen-2-yl
6-chloro-1-benzothiophen-2-yl
1-benzothiophen-5-yl 1 -methyl- 1 H-1 ,2,3-benzotriazol-6-yl imidazo[2,1-b][1 ,3]thiazol-6-yl
4-methyl-3,4-dihydro-2H-1 ,4-benzoxazin-7-yl
1-methy-1 H-indol-2-yl
1 H-pyrimido[5,4-b][1 ,4]thiazin-7(6H)-one-2-yl [1 ,2,5]thiadiazolo[3,4-fe]pyridine-6-yl
4-fluoro-1 H-benzimidazol-2-yl
3,4-dihydro-2H-chromen-7-yl
2,3-dihydro-1-benzofuran-6-yl
3,4-dihydro-2H-chromen-6-yl 6-chloro-2,3-dihydro-1 ,4-benzodioxin-7-yl
7-chloro-3,4-dihydro-2H-pyrido[3!2-b][1 ,4]oxazine-6-yl
7-chloro-3,4-dihydro-2H-pyrido[3!2-b][1 ,4]thiazine-6-yl
3,4-dihydro-2H-pyrido[3,2-fc][1 ,4]thiazin-6-yl
5-fluoro-2,3-dihydro-1 ,4-benzodioxin- 7-yl 5-fluoro-2,3-dihydro-1 ,4-benzodioxin-6-yl
8-fluoro-2H-1 ,4-benzoxazin-3(4/-/)-one-6-yl
8-fluoro-3,4-dihydro-2H-1 ,4-benzoxazin-6-yl
7,8-difluoro-3,4-dihydro-2/-/-1 ,4-benzoxazin-6-yl
6,7-dihydro-5H-thieno[3,2-b]pyran-2-yl 5-methyl-2,3-dihydro-1 ,4-benzodioxin-7-yl
4-oxo-2,3,4,5-tetrahydro-1 ,5-benzothiazepin-7-yl
3,4-dihydro-2H-1 ,4-benzothiazine-6-yl
2,3,4,5-tetrahydro-1 ,5-benzothiazepine-7-yl
7-fluoro-3,4-dihydro-2H-1 ,4-benzoxazine-6-yl
in which → is the point of attachment; especially
2,3-dihydro[1 ,4]oxathiino[2,3-c]pyridin-7-yl
3,4-dihydro-2/-/-pyrano[2,3-c]pyridin-6-yl 5-fluoro-2,3-dihydro-1 ,4-benzodioxin-7-yl 5-carbonitro-2,3-dihydro-1 ,4-benzodioxin-7-yl 2,3-dihydro-benzo[1 ,4]dioxin-6-yl
in which → is the point of attachment.
In some embodiments, R5 is: 2,3-dihydro-[1 ,4]dioxino[2,3-c]pyridin-7-yl; [1 ,3]oxathiolo[5,4-c]pyridin-6-yl; 2,3-dihydro[1 ,4]oxathiino[2,3-c]pyridin-7-yl; or 3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-yl.
In some embodiments, Z1 is CR1c, R1c is methyl, Z2 is CH, R1a and R1b are hydrogen, A is (ia) wherein n is 1 and R3 is hydrogen, R2 is hydrogen, U is CH2 and R5 is any of the embodiments defined above, including individual embodiments.
Particular examples of compounds of the invention include:
(1R)-1-({4-[(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1- piperidinyl}methyl)-6-methyl-1 ,2-dihydro-4H,9H-imidazo[1 ,2,3-/y]-1 ,8-naphthyridine-4,9- dione;
(1R)-1-({4-[(2,3-dihydro[1 ,4]oxathiino[2,3-c]pyridin-7-ylmethyl)amino]-1- piperidinyl}methyl)-6-methyl-1 ,2-dihydro-4H,9H-imidazo[1 ,2,3-/y]-1 ,8-naphthyridine-4,9- dione;
(1R)-1-({4-[(2,3-dihydro[1 ,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1- piperidinyl}methyl)-6-methyl-1 ,2-dihydro-4H,9H-imidazo[1 ,2,3-/y]-1 ,8-naphthyridine-4,9- dione; and
(1R)-6-methyl-1-({4-[([1 ,3]oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1- piperidinyl}methyl)-1 ,2-dihydro-4H,9H-imidazo[1 ,2,3-/y]-1 ,8-naphthyridine-4,9-dione; and pharmaceutically acceptable salts and/or N-oxides thereof.
When used herein, the terms "alkyl", "alkenyl", and "alkoxy" include groups having straight and branched chains.
When a range of carbon numbers is used herein, e.g. "(C-|.g)", each embodiment in the range having a particular number of carbon atoms (including a single integer or a sub-range of carbons, e.g. "(C-1.4)", "(C2-6)" etc.), is specifically included as though expressly set forth. For instance, (C-|.g)alkyl includes alkyl groups having 1 , 2, 3, 4, 5 or 6 carbons, as well as (C-1.5), (C2-g), (C3-5), etc. alkyl. Thus (C-|.g)alkyl includes all straight and branched chain alkyl groups having from 1-6 carbons, e.g. methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, pentyl and hexyl. The term 'alkenyl' should be interpreted accordingly.
Halo or halogen includes fluoro, chloro, bromo and iodo.
Haloalkyl moieties include 1-3 halogen atoms.
When a term includes "substituted alkyl," e.g. "(C-|.g)alkoxy-substituted(C-|. g)alkyl", the number of indicated substituents may be as permitted by valency and chemistry. In some embodiments, one or two (particularly one) of such substituents is present.
Also, when a term includes "substituted alkyl" or would evidently include substitution of an alkyl group (e.g., "carboxy(C-|_4)alkyl" and "hydroxy optionally substituted with (C-|.g)alkoxy-substituted(C-|.g)alkyl"), the substituent(s) may be present on any carbon atom of the alkyl group as permitted by chemistry. In some embodiments, the alkyl group is substituted in the 1 -position.
Compounds within the invention contain a heterocyclyl group and may occur in two or more tautomeric forms depending on the nature of the heterocyclyl group; all such tautomeric forms are included within the scope of the invention.
Some of the compounds of this invention may be crystallised or recrystallised from solvents such as aqueous and organic solvents. In such cases solvates may be formed. This invention includes within its scope stoichiometric solvates including hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation.
Furthermore, it will be understood that phrases such as "a compound of formula (I) or a pharmaceutically acceptable salt and/or N-oxide thereof" are intended to encompass the compound of formula (I), an N-oxide of the compound of formula (I), a pharmaceutically acceptable salt of the compound of formula (I) or any pharmaceutically acceptable combination of these. As will be understood by those skilled in the art, such compounds may be in the form of a solvate. Thus by way of non-limiting example used here for illustrative purpose, "a compound of formula (I) or a pharmaceutically acceptable salt thereof" may include a pharmaceutically acceptable salt of a compound of formula (I) that is further present as a solvate.
Since the compounds of formula (I) are intended for use in pharmaceutical compositions it will readily be understood that in particular embodiments they are provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and particularly at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions; these less pure preparations of the compounds should contain at least 1%, more suitably at least 5% and more particularly from 10% of a compound of the formula (I) or pharmaceutically acceptable salt and/or N-oxide thereof. Particular compounds according to the invention include those mentioned in the examples and their pharmaceutically acceptable salts and/or N-oxides.
Pharmaceutically acceptable salts of the above-mentioned compounds of formula (I) include the acid addition or quaternary ammonium salts, for example their salts with mineral acids e.g. hydrochloric, hydrobromic, sulphuric, nitric or phosphoric acids, or organic acids, e.g. acetic, fumaric, succinic, maleic, citric, benzoic, p-toluenesulphonic, methanesulphonic, naphthalenesulphonic acid or tartaric acids. Compounds of formula (I) may also be prepared as the N-oxide. The invention extends to all such derivatives. Certain of the compounds of formula (I) may exist in the form of optical isomers, e.g. diastereoisomers and mixtures of isomers in all ratios, e.g. racemic mixtures. The invention includes all such forms, in particular the pure isomeric forms. For example the invention includes enantiomers and diastereoisomers at the attachment point of NR^ and R3. The different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses. The invention also includes compounds of formula I in any polymorphic forms.
In a further aspect of the invention there is provided a process for preparing compounds of formula (I) where Z1 is CR1c and Z^ is CH, and pharmaceutically acceptable salts and/or N-oxides thereof, which process comprises:
reacting a compound of formula (NA):
(MA) in which:
L is an epoxide Or where and are both attached to the same carbon atom on A, Q is H and is together form ethylenedioxy or oxo, is or a group convertible thereto and is or a group convertible thereto, and A U and , are as defined in formula (I), followed by cyclisation and oxidation, to give a compound of formula (NIA):
and thereafter optionally or as necessary converting L to -A-N R^-LJ R^, interconverting any variable groups, and/or forming a pharmaceutically acceptable salt and/or N-oxide thereof.
An example of the preparation of compounds of formula (NIA) comprising reacting a compound of formula (NA) is shown in Scheme 1 starting from commercially available reagents: Scheme 1
(a) tris(dibenzylideneacetone)dipalladium(0), I^N-dicyclohexylmethylamine, bis(tri-t- butylphosphine)palladium(O), ethyl 2-butenoate (b) hydrogen, palladium/charcoal (c) acid treatment (HCI) (d) see text (e) heat (f) methanesulphonyl chloride, triethylamine (g) amine H-A(Qj )(Q^), heat (h) 2,3-dichloro-5,6-dicyano-1 ,4-benzoquinone
The reaction of known methoxypyridyl bromide (1 ) with ethyl 2-butenoate under standard Heck reaction conditions employing palladium catalysis (see Sydorenko, N, et al, Organic & Biomolecular Chemistry (2005), 3(1 1 ), 2140-2144 for an example of this type of catalysis in a Heck reaction) gives acryate (2). A mixture of olefins is possible; however, hydrogenation of the double bond of (2) will yield a single saturated product (3). Acid treatment of (3) to remove the pivalate residue and affect lactamisation yields the bicyclic lactam (4).
Conversion to the epoxide (5) can be effected in a number of ways. Reaction with epichlorohydrin under basic conditions affords racemic epoxide. Reaction with (commercially available) R or S-glycidyl nosylate ((2R)- or (2S)-2-oxiranylmethyl 3- nitrobenzenesulfonate) or (2R)- or (2S)-2-oxiranylmethyl 4-methylbenzenesulfonate, with base, e.g. sodium hydride or potassium t-butoxide, gives the corresponding chiral epoxides. Alternatively, allylation with allyl bromide under basic conditions affords the corresponding N-allyl material which can be epoxidised under standard achiral or chiral conditions to give the corresponding achiral or chiral epoxides.
Under thermal conditions, the epoxide (5) may be opened and cyclised directly to afford (6) (L=OH) which can be converted to the mesylate (7) (L=OMs). Displacement of the mesylate with amine H-A(Q-I )(Q^) such as 1 ,1-dimethylethyl 4-piperidinylcarbamate by heating in DMF affords (8). Oxidation to (9) may be carried out by oxidation of (8) with 2,3-dichloro-5,6-dicyano-1 ,4-benzoquinone (DDQ).
Subsequent conversion to compounds of formula (I) may be carried out as generally described herein. In particular, conversion of L to A(Q-I )(Q2) may be carried out on (7) or (9). As a further variation to Scheme 1 , epoxide (5) may be prepared from (2) by first introducing a suitable epoxide precursor group (-CH2-CHOH-CH2OH, protected as a cyclic ester) before carrying out the steps (b) and (c).
As shown in Scheme 1 L in (NIA) is not necessarily the same as L in (NA). As will be appreciated by those skilled in the art, L in (NA) is used to effect cyclization to the tricyclic (NIA). The resulting "L" can be modified to attach the remaining portion of compound. This applies in analogous manner to the Schemes 2-4.
L may be a hydroxy group which can be oxidised to the aldehyde by conventional means such as 1 ,1 ,1-tris-(acetyloxy)-1 ,1-dihydro-1 ,2-benziodooxol-3-(1 H)-one for reductive alkylation with HA-N(R20)R2' unc|e|- conventional conditions (see for examples Smith, M. B.; March, J. M. Advanced Organic Chemistry, Wiley-lnterscience 2001 ).
Alternatively L may be bromo which can be alkylated with HA-N(R20)R2' unc|e|- conventional conditions.
Where Q1 and Q2 together form ethylenedioxy in formula (NIA) the ketal may be converted to the ketone (Q-I and Q2 together form oxo) by conventional acid hydrolysis treatment with e.g. aqueous HCI or trifluoroacetic acid and the subsequent conversion to NR2UR5 by conventional reductive alkylation with amine NHR2 R20 (see fOr example Nudelman, A., et al, Tetrahedron 60 (2004) 1731-1748) and subsequent conversion to the required substituted amine, or directly with NHR2UR5, such as with sodium triacetoxyborohydride in dichloromethane/methanol.
Conveniently one of R20 and R2' is an N-protecting group, such as such as t- butoxycarbonyl, benzyloxycarbonyl or 9-fluorenylmethyloxycarbonyl. This may be removed by several methods well known to those skilled in the art (for examples see "Protective Groups in Organic Synthesis, T.W. Greene and P. G. M. Wuts, Wiley- Interscience, 1999), for example conventional acid hydrolysis with, for example trifluoroacetic acid or hydrochloric acid. The invention further provides compounds of formula (NIA) in which L is -A-N(R20)R2' and R20 is hydrogen.
The free amine of formula (NIA) in which R2O is hydrogen may be converted to NR2URS by conventional means such as amide formation with an acyl derivative
R^COW, for compounds where U is CO or, where U is CH2, by alkylation with an alkyl halide R^Ch^-halide in the presence of base, acylation/reduction with an acyl derivative
R^COW or reductive alkylation with an aldehyde R^CHO under conventional conditions (see for examples Smith, M. B.; March, J. M. Advanced Organic Chemistry, Wiley- Interscience 2001 ). The appropriate reagents containing the required R^ group are known compounds or may be prepared analogously to known compounds, see for example WO02/08224, WO02/50061 , WO02/56882, WO02/96907, WO2003087098, WO2003010138, WO2003064421 , WO2003064431 , WO2004002992, WO2004002490, WO2004014361 , WO2004041210,WO2004096982, WO2002050036, WO2004058144, WO2004087145, WO06002047, WO06014580, WO06010040, WO06017326,
WO06012396, WO06017468, WO06020561 , WO2004/035569, WO2004/089947, WO2003082835, WO06002047, WO06014580, WO06010040, WO06017326, WO06012396, WO06017468, WO06020561 , WO06132739, WO06134378, WO06137485, WO06081179, WO06081264, WO06081289, WO06081 178, WO06081 182, WO07016610, WO07081597, WO07071936, WO071 15947, WO071 18130, WO07122258, WO08006648, WO08003690, WO08009700, WO200706751 1 and EP0559285, each incorporated by reference herein in their entirety.
Where R^ contains an NH group, this may be protected with a suitable N- protecting group such as t-butoxycarbonyl, benzyloxycarbonyl or 9- fluorenylmethyloxycarbonyl during the coupling of the R^ derivative with the free amine of formula (NB). The protecting group may be removed by conventional methods, such as by treatment with trifluoroacetic acid.
In a further aspect of the invention there is provided a process for preparing compounds of formula (I) where where Z2 is CR1c and Z^ is CH, and pharmaceutically acceptable salts and/or N-oxides thereof, which process comprises: reacting a compound of formula (NB):
(HB) in which:
L is a leaving group or where and are both attached to the same carbon atom on A, Q^ is H and Q2 is N(R2^)R2' Or Q1 and Q2 together form ethylenedioxy or oxo , or a group convertible thereto and R2 is R2 or a group convertible thereto, and A, are as defined in formula (I), followed by cyclisation and oxidation, to give a compound of formula formula (1MB):
and thereafter optionally or as necessary converting L to -A-NR2-UR5, interconverting any variable groups, and/or forming a pharmaceutically acceptable salt and/or N-oxide thereof.
The reaction of (NB) and subsequent transformations to form (1MB) are carried out as for the preparation of compounds of formula (NIA). The invention further provides compounds of formula (1MB) in which L is -A- is hydrogen.
Compounds of formula (1MB) in which L= -A(Qi )(Q2) may be prepared by Scheme 2:
Scheme 2
(a) pivaloyl chloride, amine base (b) butyl lithium, 1 ,2-dibromoethane (c) tris(dibenzylideneacetone)dipalladium(0), N,N-dicyclohexylmethylamine, bis(tri-t- butylphosphine)palladium(O), ethyl acrylate (d) hydrogen, palladium/charcoal (e) acid treatment (HCI): As in Scheme 1 (f) see text (g) heat (h) methanesulphonyl chloride, triethylamine (i) amine H-A(Qi )(Q^), heat (j) 2,3-dichloro-5,6-dicyano-1 ,4-benzoquinone.
The commercially available 2-amino-4-methyl-6-methoxypyridine (10) may be acylated with pivaloyl chloride and an amine base such as triethylamine to give the acylated compound (11 ). Directed lithiation followed by lithium-halogen exchange with 1 ,2-dibromoethane gives brominated compound (12) (see for example Cottineau, et al, Tetrahedron 63 (2007) 10354-10362). The reaction of bromide (12) with ethyl acrylate under standard Heck reaction conditions employing palladium catalysis (see Sydorenko, N, et al, Organic & Biomolecular Chemistry (2005), 3(11 ), 2140-2144 for an example of this type of catalysis in a Heck reaction) gives olefin (13) which can be reduced under standard hydrogenation conditions to yield (14). Acid treatment of (14) to remove the pivalate residue and affect lactamisation yields the bicyclic lactam (15). The same series of reactions employed in Scheme 1 (see accompanied notes) can be utilized for the conversion of (15) to (NIB) (16).
In a further aspect of the invention there is provided a process for preparing compounds of formula (l)where Z2 is N and Z^ is CR1c, and pharmaceutically acceptable salts and/or N-oxides thereof, which process comprises:
reacting a compound of formula (NC):
(HC) in which:
L is a leaving group o where and are both attached to the same carbon atom on A is H and is O and ogether form ethylenedioxy or oxo, js U or a group convertible thereto and R^ is R^ or a group convertible thereto, and A, U and ^ are as defined in formula (I), followed by cyclisation and oxidation to give a compound of formula (NIC):
and thereafter optionally or as necessary converting L to -A-NR2-UR5, interconverting any variable groups, and/or forming a pharmaceutically acceptable salt and/or N-oxide thereof.
The reaction of (NC) and subsequent transformations is carried out as for the preparation of compounds of formula (NIB).
The invention further provides compounds of formula (NIC) in which L is -A-
N(R20)R2' and R20 is hydrogen.
Compounds of formula (NIC) in which L= -A(Qi )(Q2) may be prepared by Scheme 3:
Scheme 3
(a) sodium methoxide (b) N-Bromosuccinamide (c) tris(dibenzylideneacetone)dipalladium(0), N,N-dicyclohexylmethylamine, bis(tri-t- butylphosphine)palladium(O), ethyl 2-butenoate (d) hydrogen, palladium/charcoal (e) acid treatment (HOAc) (f) R or S-glycidyl nosylate, inorganic base (see text as for Scheme 1 ); as in Scheme 1 : (g) heat (h) methanesulphonyl chloride, triethylamine (i) amine H-
A(Qj )(Q2), heat (j) 2,3-dichloro-5,6-dicyano-1 ,4-benzoquinone. The commercially available 2-amino-6-chloropyrazine (17) can undergo a nucleophilic displacement with sodium methoxide to give (18). Bromination with NBS gives predominately 2-Amino-3-bromo-6-methoxy-pyrazine (19) (see for related example Barlaam, B., et al, Bioorg. & Med. Chem Lett. 15 (2005) 5446-5449). The reaction of bromide (19) with ethyl 2-butenoate under standard Heck reaction conditions employing palladium catalysis (see Sydorenko, N, et al, Organic & Biomolecular Chemistry (2005), 3(11 ), 2140-2144 for an example of this type of catalysis in a Heck reaction) gives acryate (20). A mixture of olefins is possible; however, hydrogenation of the double bond of (20) will yield a single saturated product (21 ). Mild acid treatment of (21 ) to affect lactamisation yields the bicyclic lactam (22).
The same series of reactions employed in Scheme 1 (see text) can be utilized for the conversion to (NIC) (24).
In a further aspect of the invention there is provided a process for preparing compounds of formula (I) where where Z2 is CR1c and Z^ is N, and pharmaceutically acceptable salts and/or N-oxides thereof, which process comprises:
reacting a compound of formula (ND):
(MD) in which L is a leaving group are both attached to the same carbon atom Or Q1 and Q^ together form ethylenedioxy or oxo, R^O js UR^ or a group convertible thereto and R^' is R^ or a group convertible thereto, and A re as defined in formula (I), followed by cyclisation and oxidation to give a compound of formula (NID):
and thereafter optionally or as necessary converting L to -A-NR2-UR5, interconverting any variable groups, and/or forming a pharmaceutically acceptable salt and/or N-oxide thereof.
The reaction of (ND) and subsequent transformations are carried out as for the preparation of compounds of formula (NIC).
The invention further provides compounds of formula (NID) in which L is -A- N(R20)R2' and R20 is hydrogen. Compounds of formula (HID) in which L= -A(Q^ )(Q2) may be prepared by
Scheme 4:
Scheme 4
(25) (26) (27)
(a) Hydrogen, palladium/charcoal (b) ethyl bromoacetate, inorganic base (c) Benzyl chloroformate (d) R or S-glycidyl nosylate, inorganic base (e) heat (f) Hydrogen, palladium/charcoal (g) Mnθ2 (h) methanesulfonyl chloride (i) amine H-A(Q^ )(Q2), heat
Reduction of aminonitropyridine (24) under standard hydrogenation conditions leads to bis-aniline (25). Alkyation with ethyl bromoacetate followed by cyclisation with potassium te/f-butoxide gives (26). This is protected with a carboxybenzyl group to give (27) which can then be reacted with (commercially available) S-glycidyl nosylate ((2S)-2- oxiranylmethyl 3-nitrobenzenesulfonate) to give (28). Cyclisation under thermal conditions gives (29). Hydrogenolysis of the CBz group (30) and subsequent oxidation with manganese(ll)oxide (31 ), followed by mesylation and displacement with an appropriate amine gives representatives of (NID) (34) (L is -A(Q^ )(Q2)).
Interconversions of R^ a, R-"3, R^, A and R^ are conventional. In compounds which contain an optionally protected hydroxy group, suitable conventional hydroxy protecting groups which may be removed without disrupting the remainder of the molecule include acyl and alkylsilyl groups. N-protecting groups are removed by conventional methods.
Interconversion of R^ a and R-"3 groups may be carried out conventionally, on compounds of formula (I). For example R^ a or R""3 methoxy is convertible to R^ a or
R""3 hydroxy by treatment with lithium and diphenylphosphine (general method described in Ireland et al, J. Amer. Chem. Soc, 1973, 7829) or HBr. Alkylation of the hydroxy group with a suitable alkyl derivative bearing a leaving group such as halide, yields R^ a or R""3 substituted alkoxy. R^ a or R""3 halo such as bromo may be converted to cyano by treatment with copper (I) cyanide in N,N-dimethylformamide. R^a or R""3 carboxy may be obtained by conventional hydrolysis of R^ a or R-"3 cyano, and the carboxy converted to hydroxymethyl by conventional reduction.
Compounds of formula HA-N(R20)R2' are known compounds or may be prepared analogously to known compounds, see for example WO2004/035569, WO2004/089947, WO02/08224, WO02/50061 , WO02/56882, WO02/96907, WO2003087098, WO2003010138, WO2003064421 , WO2003064431 , WO2004002992, WO2004002490, WO2004014361 , WO2004041210.WO2004096982, WO2002050036, WO2004058144, WO2004087145, WO2003082835, WO2002026723, WO06002047 and WO06014580, WO06134378, WO06137485, WO07016610, WO07081597, WO07071936, WO071 15947, WO07118130, WO07122258, WO08006648, WO08003690 and WO08009700, each incorporated by reference herein in their entirety. Further details for the preparation of compounds of formula (I) are found in the examples. The antibacterial compounds according to the invention may be formulated for administration in any convenient way for use in human or veterinary medicine, by analogy with other antibacterials compounds.
The pharmaceutical compositions of the invention may be formulated for administration by any route and include those in a form adapted for oral, topical or parenteral use and may be used for the treatment of bacterial infection in mammals including humans.
The compositions may be in the form of tablets, capsules, powders, granules, lozenges, suppositories, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions.
The topical formulations of the present invention may be presented as, for instance, ointments, creams or lotions, eye ointments and eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration, and emollients in ointments and creams.
The formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions. Such carriers may be present as from about 1 % up to about 98% of the formulation. More usually they will form up to about 80% of the formulation. Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives, such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and, if desired, conventional flavouring or colouring agents.
Suppositories will contain conventional suppository bases, e.g. cocoa-butter or other glyceride. For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, agents such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. The dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use. Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound. The compositions may contain from 0.1 % by weight, preferably from 10-60% by weight, of the active material (e.g. compound of formula (I) or pharmaceutically acceptable salt and/or N-oxide thereof), depending on the method of administration. Where the compositions comprise dosage units, each unit will preferably contain from 50-1000 mg of the active ingredient. The dosage as employed for adult human treatment will preferably range from 100 to 3000 mg per day, for instance 1500 mg per day depending on the route and frequency of administration. In some embodiments from about 1.5 to about 50 mg active/kg patient body weight is administered per day. Suitably the dosage is from 5 to 30 mg/kg per day.
The compound of formula (I) may be the sole therapeutic agent in the compositions of the invention or a combination with other antibacterials including antitubercular compounds. If the other antibacterial is a β-lactam then a β-lactamase inhibitor may also be employed.
Compounds of formula (I) may be used to inhibit the growth of one or more of a wide range of organisms including both Gram-negative and Gram-positive organisms, including, for example, one or more of: Hemophilus influenzae, Klebsiella pneumoniae,
Legionella pneumoniae
Pseudomonas aeruginosa,
Escherichia coli, Proteus mirabilis,
Enterobacter cloacae,
Enterobacter aerogenes,
Serratia marcescens,
Helicobacter pylori, Salmonella enteritidis,
Salmonella typhi,
Acinetobacter baumanii,
Neisseria gonorrhoeae,
Neisseria meningitides, Moraxella catarrhalis,
Mycobacterium tuberculosis,
Streptococcus pneumoniae,
Streptococcus pyogenes,
Staphylococcus aureus, Enterococcus faecalis,
Enterococcus faecium,
Chlamydia pneumoniae, and
Staphylococcus epidermidis.
Some compounds of formula (I) may be active against more than one organism.
In some embodiments, compounds of the invention have activity against one or more of:
Hemophilus influenzae,
Klebsiella pneumoniae, Pseudomonas aeruginosa,
Escherichia coli,
Proteus mirabilis,
Enterobacter cloacae,
Enterobacter aerogenes, Moraxella catarrhalis,
Mycobacterium tuberculosis, Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium.
Compounds of formula (I) may therefore be used in the treatment of bacterial infections caused by a wide range of organisms including both Gram-negative and Gram-positive organisms, including the above-listed organisms, such as upper and/or lower respiratory tract infections, skin and soft tissue infections and/or urinary tract infections, including for example tuberculosis caused by Mycobacterium tuberculosis.
Antibacterial activity may be determined by the methods described herein.
The following examples illustrate the preparation of certain compounds of formula (I) and the activity of certain compounds of formula (I) against various bacterial organisms.
Examples and Experimental
General
Abbreviations in the examples:
MS = mass spectrum ES = Electrospray mass spectroscopy
LCMS/LC-MS = Liquid chromatography mass spectroscopy
HPLC = high performance liquid chromatography rt = room temperature
Rf = retention factor
Certain reagents are also abbreviated herein. TFA refers to trifluoroacetic acid,
THF refers to tetrahydrofuran, Pd/C refers to palladium on carbon catalyst, DCM refers to dichloromethane, MeOH refers to methanol, DMF refers to dimethylformamide, EtOAc refers to ethylacetate, DDQ refers to 2,3-dichloro-5,6-dicyano-1 ,4-benzoquinone, NaBH(OAc)3 refers to sodium triacetoxyborohydride, Pd2(dba)3 refers to tris(dibenzylideneacetone)dipalladium (0).
Proton nuclear magnetic resonance (1H NMR) spectra were recorded at 400 or
250 MHz, and chemical shifts are reported in parts per million (ppm) downfield from the internal standard tetramethylsilane (TMS). Abbreviations for NMR data are as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, dt = doublet of triplets, td = triplet of doublets, app = apparent, br = broad. J indicates the
NMR coupling constant measured in Hertz. CDCI3 is deuteriochloroform and CD3OD is tetradeuteriomethanol. Mass spectra were obtained using electrospray (ES) ionization techniques. All temperatures are reported in degrees Celsius. MP-carbonate refers to macroporous triethylammonium methylpolystyrene carbonate (Argonaut Technologies). Amberlyst®A21 is a weakly basic, macroreticular resin with alkyl amine functionality, ©Registered trademark of Rohm & Haas Co.
AD mix alpha is prepared by mixing potassium osmate (K2OsO4.2H2O) (0.52g), (3a,9R,3'"a,4'"b,9'"R)-9,9'-[1 ,4-phthalazinediylbis(oxy)]bis[6'-(methyloxy)-10, 11 - dihydrocinchonan] [(DHQ)2PHAL] (5.52g), then adding potassium ferricyanide
[K3Fe(CN)6] (70Og) and powdered potassium carbonate (294g). This mixture is stirred in a blender for 30 minutes. This provides approximately 1 kg of AD mix alpha, which is commercially available from Aldrich. See K. Barry Sharpless et al, J. Org. Chem., 1992, 57 (10), 2771. AD mix beta is the corresponding mixture prepared with (9S,9'"S)-9,9'- [1 ,4-phthalazinediylbis(oxy)]bis[6'-(methyloxy)-10, 11-dihydrocinchonan] [(DHQD)2PHAL].
Where AD mix alpha/beta is referred to, this is a 1 :1 mixture of the alpha and beta mix. Celite® is a filter aid composed of acid-washed diatomaceous silica, and is a trademark of Manville Corp., Denver, Colorado.
SCX Cartridge is an ion exchange column containing strong cation exchange resin ( benzene sulfonic acid) supplied by Varian, USA. Chiralpak IA and Chiralpak AS-H are polysaccharide based chiral HPLC columns
(Chiral Technologies Inc.). Chiralpak AS-H column comprise amylose tris [(S)- alpha- methylbenzylcarbamate) coated onto 5μm silica. Chiralpak IA column comprise silica for preparative column (5μm particle size, 21 mm ID x 250mm L ) immobilized with Amylose tris (3,5-dimethylphenylcarbamate). Chiralpak AD and AD-H columns comprise silica for preparative columns (5μm particle size AD-H and 10μm particle size AD, 21 mm ID x
250mm L; 20 μM particle size AD, 101 mm ID x 250mm L) coated with Amylose tris (3,5- dimethylphenylcarbamate) (Chiral Technologies USA). Measured retention times are dependent on the precise conditions of the chromatographic procedures. Where quoted below in the Examples they are indicative of the order of elution. Kromasil 5 micron C-18 column (21 mm x 250mm) comprises octadecylsilane chemically bonded to 5 micron porous silica gel.
As will be understood by the skilled chemist, references to preparations carried out in a similar manner to, or by the general method of, other preparations, may encompass variations in routine parameters such as time, temperature, workup conditions, minor changes in reagent amounts etc.
Reactions involving metal hydrides including lithium hydride, lithium aluminium hydride, di-isobutylaluminium hydride, sodium hydride, sodium borohydride and sodium triacetoxyborohydride are carried out under argon or other inert gas.
Example 1 (1/?)-1-({4-[(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1- piperidinyl}methyl)-6-methyl-1 ,2-dihydro-4H,9H-imidazo[1 ,2,3-/y]-1 ,8-naphthyridine- 4,9-dione hydrochloride
(a) N-[3-bromo-6-(methyloxy)-2-pyridinyl]-2,2-dimethylpropanamide
A solution of 2,2-dimethyl-N-[6-(methyloxy)-2-pyridinyl]propanamide (10 g, 48.0 mmol) in tetrahydrofuran (100 ml) under Argon was cooled to -780C and then treated with n-butyllithium (42.3 ml, 106 mmol, 2.5M solution in hexanes) over 20 minutes. The reaction was then allowed to warm to O0C and was stirred at O0C for 4h. The clear reaction went yellow and then a solid crushed out. The mixture was then recooled to -
780C and treated with 1 ,2-dibromoethane (4.97 ml, 57.6 mmol) over 5 minutes. The solution was allowed to warm to room temperature and was stirred at room temperature for 30minutes. Water (2OmL) was then carefully added followed by further water (8OmL) and the mixture was extracted with diethyl ether (3x10OmL).
Combined organics were dried (MgSO4), filtered and evaporated to give the crude product which was dissolved in warm ethyl acetate (2OmL) and allowed to stand in the freezer overnight. The solid that crystallised out was filtered off, washed with ice- cooled diethyl ether (~5mL) and dried in vacuo to afford 6.9g of the desired product as a white solid (50%).
The filtrate was evaporated to afford ~5g of crude which was purified by silica chromatography (0-15% EtOAc/40-60 petr. ether) to afford more of the desired product (2.45g, 17.8%). MS (ES+) m/z 287/289 (MH+)
(b) Ethyl (2£)-3-[2-[(2,2-dimethylpropanoyl)amino]-6-(methyloxy)-3-pyridinyl]-2-butenoate N2479-61-A2 and ethyl 3-[2-[(2,2-dimethylpropanoyl)amino]-6-(methyloxy)-3-pyridinyl]-3- butenoate
A mixture of N-[3-bromo-6-(methyloxy)-2-pyridinyl]-2,2-dimethylpropanamide (8.25g, 28.7 mmol), bis(tri-t-butylphosphine)palladium(0) (0.147 g, 0.287 mmol) and tris(dibenzylideneacetone)dipalladium(0) (0.526 g, 0.575 mmol) in dry, degassed 1 ,4- Dioxane (150 ml) was treated with ethyl (2E)-2-butenoate (4.29 ml, 34.5 mmol) and dicyclohexyl(methyl)amine (6.70 ml, 31.6 mmol) at room temperature under Argon. The reaction mixture was heated at reflux (the colour of the reaction changed from burgundy to yellow). After 2h there was still 12% of product so the reaction was stirred at reflux overnight. There was still some starting material (9%) present but reaction was getting messy so the solvent was removed and water (25OmL) was added and extracted with diethyl ether (3x250ml_). Combined organics were dried (MgSO4), filtered and evaporated to afford 9.4g of crude which was purified by silica chromatography (0-35% EtOAc-40-60 pet.ether) to afford ethyl (2E)-3-[2-[(2,2-dimethylpropanoyl)amino]-6- (methyloxy)-3-pyridinyl]-2-butenoate as an orange oil (1.85g, 20.1 %) . MS (ES+) m/z 321 (MH+) Also ethyl 3-[2-[(2,2-dimethylpropanoyl)amino]-6-(methyloxy)-3-pyridinyl]-3- butenoate was obtained as a yellow oil (0.8g, 8.7%) MS (ES+) m/z 321 (MH+)
(c) Ethyl 3-[2-[(2,2-dimethylpropanoyl)amino]-6-(methyloxy)-3-pyridinyl]butanoate
Ethyl 3-[2-[(2,2-dimethylpropanoyl)amino]-6-(methyloxy)-3-pyridinyl]-3-butenoate (0.8g, 2.497 mmol) was dissolved in ethanol (50 ml) at room temperature and then treated with palladium on carbon (0.9 g, 10% paste). Everything was stirred at room temperature under 1 atm of hydrogen over the weekend. The reaction was complete so it was filtered through a celite pad and the pad was washed with more ethanol (15OmL). The ethanol was evaporated to afford the desired product as a white solid (0.75g, 93%). MS (ES+) m/z 323(MH+)
(d) Ethyl 3-[2-[(2,2-dimethylpropanoyl)amino]-6-(methyloxy)-3-pyridinyl]butanoate
Ethyl (2E)-3-[2-[(2,2-dimethylpropanoyl)amino]-6-(methyloxy)-3-pyridinyl]-2- butenoate (1.85 g, 5.77 mmol) was dissolved in ethanol (100 ml) at room temperature and then treated with palladium on carbon (1.5 g, 10% paste). Everything was stirred at room temperature under 1 atm of hydrogen over the weekend. The reaction was complete so it was filtered through a celite pad and the pad was washed with more ethanol (10OmL). The ethanol was evaporated to afford the product as a white solid (1.72g, 92%). MS (ES+) m/z 323(MH+)
(e) Ethyl 3-[2-[(2,2-dimethylpropanoyl)amino]-6-(methyloxy)-3-pyridinyl]butanoate
A mixture of ethyl 3-[2-[(2,2-dimethylpropanoyl)amino]-6-(methyloxy)-3- pyridinyl]butanoate (2.82 g, 8.75 mmol) in hydrochloric acid (5M) (30 ml, 150 mmol) was heated at 800C. There was no starting material left after 3h so the reaction was cooled, treated with water (3OmL), transferred to a conical flask and neutralised with potassium carbonate. The aqueous was then extracted with 20% methanol/DCM (3x80mL). Combined organics were dried (MgSO4), filtered and evaporated to afford the desired product as a white solid (1.36g, 81 %). MS (ES+) m/z 193(MH+)
(f) 4-Methyl-7-(methyloxy)-1-[(2R)-2-oxiranylmethyl]-3,4-dihydro-1 ,8-naphthyridin-2(1 H)- one
4-methyl-7-(methyloxy)-3,4-dihydro-1 ,8-naphthyridin-2(1 H)-one (1.36 g, 7.08 mmol) was dissolved in N,N-Dimethylformamide (30 ml) at room temperature under nitrogen to give a yellow solution. The solution was then cooled with an ice bath and treated with sodium hydride (0.340 g, 8.49 mmol, 60% in mineral oil). The solution turned orange and after 10 minutes the ice bath was removed. After 20 minutes (2S)-2- oxiranylmethyl 3-nitrobenzenesulfonate (1.926 g, 7.43 mmol) was added. After 1 h all the starting material was consumed so the reaction was treated with a saturated aqueous solution of sodium bicarbonate (10OmL) and the aqueous was extracted with DCM (3x10OmL). The combined organic layers were dried (NaSO4), filtered and evaporated to afford the desired product as a brown thick oil (1.9g, 97%, 90% purity). MS (ES+) m/z 249(MH+)
(g) (1 S)-1-(hydroxymethyl)-6-methyl-1 ,2,5,6-tetrahydro-4H,9H-imidazo[1 ,2,3-ij]-1 ,8- naphthyridine-4,9-dione
4-Methyl-7-(methyloxy)-1-[(2/?)-2-oxiranylmethyl]-3,4-dihydro-1 ,8-naphthyridin- 2(1 H)-one (1.9 g, 6.89 mmol) was dissolved in N,N-Dimethylformamide (15 ml) at room temperature and heated at 1300C for 10.5h.
The DMF was then evaporated and the residue dried under high vacuum to afford a brown gum which was treated with ethyl acetate (25mL) and sonicated for 10 minutes. The solid that crushed out was filtered off, washed with 5mL of ethyl acetate and dried under vacuum overnight to afford the desired product as a brown solid (1.39g, 67%). MS (ES+) m/z 235(MH+) The filter was washed with some methanol and DCM; the solvents were evaporated to afford 0.1g of desired product as a brown solid (5%) MS (ES+) m/z 235(MH+)
(h) [(2S)-7-methyl-4,9-dioxo-1 ,2,8,9-tetrahydro-4H,7H-imidazo[1 ,2,3-ij]-1 ,8- naphthyridin- 2-yl]methyl methanesulfonate
(1 S)-1-(hydroxymethyl)-6-methyl-1 ,2,5,6-tetrahydro-4H,9H-imidazo[1 ,2,3-ij]-1 ,8- naphthyridine-4,9-dione (1.39 g, 4.75 mmol) was suspended in dichloromethane (100 ml) at room temperature under nitrogen and then treated with triethylamine (0.794 ml, 5.70 mmol). The mixture was then cooled using an ice-water bath. Methanesulfonyl chloride (0.444 ml, 5.70 mmol) was then added and the reaction allowed to warm up to room temperature. After 1 h there was still starting material present so 0.53ml_ of triethylamine and 0.3 ml. of methanesulfonyl chloride were added. After 3h there was still starting material so 0.2ml_ of triethylamine and 0.2 ml. of methanesulfonyl chloride were added. After 1 h the reaction was complete so the mixture was washed with a saturated solution of sodium bicarbonate(100ml_); the aqueous was extracted with DCM (2x10OmL) and the combined organics were dried (NaSO4), filtered and evaporated to afford the desired product as a brown gum (1.45g, 98%). Used without further purification. MS (ES+) m/z 313(MH+) (i) 1 ,1-Dimethylethyl (1-{[(2R)-7-methyl-4,9-dioxo-1 ,2,8,9-tetrahydro-4H,7H- imidazo[1 ,2,3-ij]-1 ,8-naphthyridin-2-yl]methyl}-4-piperidinyl)carbamate
[(2S)-7-methyl-4,9-dioxo-1 ,2,8,9-tetrahydro-4H,7H-imidazo[1 ,2,3-ij]-1 ,8- naphthyιϊdin-2-yl]methyl methanesulfonate (1.579 g, 5.06 mmol) was dissolved in dry Acetonitrile (100 ml) at room temperature under nitrogen and treated with pyridine (0.818 ml, 10.11 mmol). 1 ,1-dimethylethyl 4-piperidinylcarbamate (2.109 g, 10.11 mmol) was then added and the reaction was heated at 90 0C overnight. After night there was still 15% of starting material left so 0.5g of 1 ,1-dimethylethyl 4-piperidinylcarbamate were added and the reaction was heated for 6h. The solvent was then evaporated and the residue was partitioned between sat NaHCO3 and DCM (100/10OmL). The layers were separated and the aqueous was extracted with DCM again (2x10OmL). Combined organics were dried (MgSO4), filtered and evaporated to afford ~3g of crude which was purified by silica chromatography (0-10% MeOH/DCM) to afford the desired product as a yellow gum (666mg, 31.6%). MS (ES+) m/z 417(MH+)
(j) 1 , 1 -Dimethylethyl (1 -{[(1 R)-6-methyl-4,9-dioxo-1 ,2-dihydro-4H,9H-imidazo[1 ,2,3-ij]- 1 ,8-naphthyridin-1-yl]methyl}-4-piperidinyl)carbamate
A solution of 1 ,1 -dimethylethyl (1-{[(2R)-7-methyl-4,9-dioxo-1 ,2,8,9-tetrahydro- 4H,7H-imidazo[1 ,2,3-ij]-1 ,8-naphthyridin-2-yl]methyl}-4-piperidinyl)carbamate (666mg, 1.599 mmol) in dry degassed 1 ,4-Dioxane (50 ml) at rt under nitrogen was treated with DDQ (1089 mg, 4.80 mmol) and then heated at 80 0C for 2h. LC-MS showed that the reaction was complete so the reaction was cooled to rt. The reaction mixture was treated with aqueous K2CO3 (5%, 10OmL) and with DCM (100ml); the organic layer was separated and the aqueous was extracted with DCM (2 x 100ml). The combined organic layers were then dried (NaSO4), filtered and evaporated to give 550mg of crude product as an orange solid. The crude was purified on a silica column (0-10% MeOH/DCM) to give 1 , 1 -dimethylethyl (1 -{[(1 R)-6-methyl-4,9-dioxo-1 ,2-dihydro-4H,9H-imidazo[1 ,2,3-ij]- 1 ,8-naphthyridin-1-yl]methyl}-4-piperidinyl)carbamate (450 mg, 0.977 mmol, 61.1 % yield) as an orange solid. MS (ES+) m/z 415(MH+)
(k) (1 /?)-1-[(4-amino-1-piperidinyl)methyl]-6-methyl-1 ,2-dihydro-4H,9H-imidazo[1 ,2,3-/y]- 1 ,8-naphthyridine-4,9-dione dihydrochloride
A solution of 1 ,1 -dimethylethyl (1-{[(1 R)-6-methyl-4,9-dioxo-1 ,2-dihydro-4H,9H- imidazo[1 ,2,3-ij]-1 ,8-naphthyridin-1-yl]methyl}-4-piperidinyl)carbamate (450 mg, 1.086 mmol) in chloroform (8 ml) at room temperature was treated with 4M HCI in dioxane (8mL). A solid crushed out and the mixture was stirred at room temperature. After 0.5h there was no starting material left so some methanol was added to dissolve most of the solid, followed by toluene and all the solvents were removed to afford (1 /?)-1-[(4-amino- 1-piperidinyl)methyl]-6-methyl-1 ,2-dihydro-4H,9H-imidazo[1 ,2,3-ij]-1 ,8-naphthyridine-4,9- dione dihydrochloride (423 mg, 0.928 mmol, 86 % yield) as a pale brown solid. MS (ES+) m/z 314(MH+)
(I) Title compound
A suspension of (1 /?)-1-[(4-amino-1-piperidinyl)methyl]-6-methyl-1 ,2-dihydro- 4H,9H-imidazo[1 ,2,3-ij]-1 ,8-naphthyridine-4,9-dione dihydrochloride (50mg, 0.135 mmol) in chloroform (4 ml) and methanol (0.200 ml) at room temperature under nitrogen was treated with triethylamine (0.057 ml, 0.406 mmol) and stirred for 0.25h (the suspension turned into a solution). 3,4-Dihydro-2H-pyrano[2,3-c]pyridine-6-carbaldehyde (for a synthesis see WO2004058144, example 5(c)) (22.06 mg, 0.135 mmol) was then added and the reaction was stirred at room temperature for 0.5h.
Sodium triacetoxyborohydride (90 mg, 0.406 mmol) was then added and the reaction was stirred at room temperature. After 2h there was still some starting material so 30 mg of sodium triacetoxyborohydride were added. After 1 h sat NaHCO3 (25ml_) was added followed by 20% MeOH/DCM (25ml_) and the aqueous was extracted and then separated from the organic layer. The aqueous was extracted again twice with 20%MeOH/DCM (2x25ml_). Combined organics were dried NaSO4, filtered and evaporated to afford the crude. The crude was purified by silica chromatography (0- 20%MeOH/DCM) to afford 41 mg of desired compound (65.7%) as a pale yellow gum. 1H NMR δH CDCI3, (400MHz) 1.30-1.45 (m, 2H), 1.80-1.89 (m, 2H), 1.99-2.05 (m, 2H), 2.15-2.4 (m, 5H), 2.45-2.58 (m, 1 H), 2.62-2.67 (m, 2H), 2.74-2.78 (m, 2H), 2.96 (d, 1 H), 3.05-3.09 (m, 1 H), 3.79 (s, 2H), 4.19-4.22 (m, 2H), 4.28-4.33 (m, 1 H), 4.51-4.55 (m, 1 H), 4.95-5.05 (m, 1 H), 6.15 (s, 1 H), 6.26 (d, 1 H), 6.97 (s, 1 H), 7.56 (d, 1 H), 8.07 (s, 1 H). MS (ES+) m/z 462 (MH+).
The compound was dissolved in a small amount of MeOH/DCM and treated with 1eq of a 1 M solution of HCI in diethyl ether. The solvents were removed and the solid was dried in the desiccator (in the presence of P2O5) overnight to afford the mono-HCI salt of the product as a yellow solid (45.9mg, 64.8%). LCMS was consistent with product. Example 2 (1/?)-1-({4-[(2,3-dihydro[1 ,4]oxathiino[2,3-c]pyridin-7- ylmethyl)amino]-1 -piperidinyl}methyl)-6-methyl-1 ,2-dihydro-4H,9H-imidazo[1 ,2,3-
/y]-1,8-naphthyridine-4,9-dione hydrochloride
A suspension of (1 /?)-1-[(4-amino-1-piperidinyl)methyl]-6-methyl-1 ,2-dihydro-
4H,9H-imidazo[1 ,2,3-ij]-1 ,8-naphthyridine-4,9-dione (50mg, 0.135 mmol) (2HCI salt) in Chloroform (4 ml) and Methanol (0.200 ml) at room temperature under nitrogen was treated with triethylamine (0.057 ml, 0.406 mmol) and stirred for 0.25h (the suspension turned into a solution). 2,3-dihydro[1 ,4]oxathiino[2,3-c]pyridine-7-carbaldehyde (for a synthesis see WO2004058144, Example 60) (24.50 mg, 0.135 mmol) was then added and the reaction was stirred at room temperature for 0.5h. Sodium triacetoxyborohydride (90 mg, 0.406 mmol) was then added and the reaction was stirred at room temperature. After 2h there was still some starting material so 30 mg of sodium triacetoxyborohydride were added. After 1 h sat NaHCO3 (25ml_) was added followed by 20% MeOH/DCM (25ml_) and the aqueous was extracted and then separated from the organic layer. The aqueous was extracted again twice with 20%MeOH/DCM (2x25ml_). Combined organics were dried (NaSO4), filtered and evaporated to afford the crude. The crude was purified by silica chromatography (0-20%MeOH/DCM) to afford 44mg of desired compound (67.9%) as a pale yellow solid. 1H NMR δH CDCI3, (400MHz) 1.25-1.45 (m, 2H), 1.79-1.88 (m, 2H), 2.19-2.40 (m, 5H), 2.43-2.54 (m, 1 H), 2.62-2.67 (m, 2H), 2.96 (d, 1 H), 3.05-3.09 (m, 1 H), 3.15-3.18 (m, 2H), 3.76 (s, 2H), 4.28-4.33 (m, 1 H), 4.39-4.42 (m, 2H), 4.51-4.55 (m, 1 H), 4.95-5.05 (m, 1 H), 6.14 (s, 1 H), 6.26 (s, 1 H), 6.99 (s, 1 H), 7.55 (d, 1 H), 8.01 (s, 1 H). MS (ES+) m/z 480 (MH+). The compound was dissolved in a small amount of MeOH/DCM and treated with
1eq of a 1 M solution of HCI in Et20. The solvents were removed and the solid was dried in the desiccator (P2O5) overnight to afford the mono-HCI salt of the product as a yellow solid (48.5mg, 66%). LCMS was consistent with product. Example 3 (1/?)-1-({4-[(2,3-dihydro[1 ,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-
1-piperidinyl}methyl)-6-methyl-1,2-dihydro-4H,9H-imidazo[1 ,2,3-/y]-1,8- naphthyridine-4,9-dione hydrochloride
A suspension of (1 /?)-1-[(4-amino-1-piperidinyl)methyl]-6-methyl-1 ,2-dihydro-
4H,9H-imidazo[1 ,2,3-ij]-1 ,8-naphthyridine-4,9-dione (50mg, 0.135 mmol) (2HCI salt) in chloroform (4 ml) and methanol (0.200 ml) at room temperature under nitrogen was treated with triethylamine (0.057 ml, 0.406 mmol) and stirred for 0.25h (the suspension turned into a solution). 2,3-dihydro[1 ,4]dioxino[2,3-c]pyridine-7-carbaldehyde (22.33 mg, 0.135 mmol) (for a synthesis see WO2004058144 Example 2(c) or WO03/087098 Example 19(d)) was then added and the reaction was stirred at room temperature for 0.5h. Sodium triacetoxyborohydride (90 mg, 0.406 mmol) was then added and the reaction was stirred at room temperature. After 1.5h sat NaHCO3 (25ml_) was added followed by 20% MeOH/DCM (25ml_) and the aqueous was extracted and then separated from the organic layer. The aqueous layer was extracted again twice with 20%MeOH/DCM (2x25ml_). Combined organics were dried (NaSO4), filtered and evaporated to afford the crude. The crude was purified by silica chromatography (0- 20%MeOH/DCM) to afford 44.2 mg of desired compound (70.5%) as an off-white solid. 1H NMR δH CDCI3, (400MHz) 1.28-1.45 (m, 2H), 1.80-1.89 (m, 2H), 2.19-2.34 (m, 5H), 2.45-2.55 (m, 1 H), 2.62-2.67 (m, 2H), 2.96 (d, 1 H), 3.05-3.09 (m, 1 H), 3.78 (s, 2H), 4.27- 4.34 (m, 5H), 4.51-4.585 (m, 1 H), 4.95-5.05 (m, 1 H), 6.15 (s, 1 H), 6.26 (d, 1 H), 6.81 (s, 1 H), 7.56 (d, 1 H), 8.10 (s, 1 H). MS (ES+) m/z 464 (MH+).
The compound was dissolved in a small amount of MeOH/DCM and treated with 1eq of a 1 M solution of HCI in Et2O. The solvents were removed and the solid was dried in the desiccator (P2O5) overnight to afford the mono-HCI salt of the product as an off- white solid (46.9mg, 65.9%). LCMS was consistent with product. Example 4 (1/?)-6-methyl-1-({4-[([1,3]oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]- 1 -piperidinyl}methyl)-1 ,2-dihydro-4H,9H-imidazo[1 ,2,3-/y]-1 ,8-naphthyridine-4,9- dione hydrochloride
A suspension of (1 /?)-1-[(4-amino-1-piperidinyl)methyl]-6-methyl-1 ,2-dihydro-
4H,9H-imidazo[1 ,2,3-ij]-1 ,8-naphthyridine-4,9-dione (50mg, 0.135 mmol) (2HCI salt) in Chloroform (4 ml) and Methanol (0.200 ml) at room temperature under nitrogen was treated with triethylamine (0.057 ml, 0.406 mmol) and then stirred for 0.25h (the suspension turned into a solution). [1 ,3]oxathiolo[5,4-c]pyridine-6-carbaldehyde (22.60 mg, 0.135 mmol) (for a synthesis see WO2004058144 Example 61 )was then added and the reaction was stirred at room temperature for 0.5h.
Sodium triacetoxyborohydride (90 mg, 0.406 mmol) was then added and the reaction was stirred at room temperature. After 1.5h sat NaHCO3 (25ml_) was added followed by 20% MeOH/DCM (25ml_) and the aqueous was extracted and then separated from the organic layer, the aqueous was extracted again twice with 20%MeOH/DCM (2x25ml_). Combined organics were dried (NaSO4), filtered and evaporated to afford the crude. The crude was purified by silica chromatography (0- 20%MeOH/DCM) to afford 44.2 mg of desired product (70.5%) as an off-white solid. 1H NMR δH CDCI3, (400MHz) 1.20-1.45 (m, 2H), 1.70-2.00 (m, 2H), 2.15-2.40 (m, 5H), 2.45-2.55 (m, 1 H), 2.60-2.70 (m, 2H), 2.95 (d, 1 H), 3.05-3.15 (m, 1 H), 3.80 (s, 2H), 4.25- 4.35 (m, 1 H), 4.50-4.60 (m, 1 H), 4.95-5.05 (m, 1 H), 5.62 (s, 2H), 6.15 (s, 1 H), 6.26 (d, 1 H), 7.20 (s, 1 H), 7.56 (d, 1 H), 8.00 (s, 1 H). MS (ES+) m/z 466 (MH+).
The compound was dissolved in a small amount of MeOH/DCM and treated with 1eq of a 1 M solution of HCI in Et20. The solvents were removed and the solid was dried in the desiccator (P2O5) over the weekend to afford the mono-HCI salt of the product as an off-white solid (48.1 mg, 67.3%). LCMS was consistent with product. Biological Activity
Antimicrobial Activity Assay:
Whole-cell antimicrobial activity was determined by broth microdilution using the Clinical and Laboratory Standards Institute (CLSI) recommended procedure, Document M7-A7, "Methods for Dilution Susceptibility Tests for Bacteria that Grow Aerobically". The compounds were tested in serial two-fold dilutions ranging from 0.016 to 16 mcg/ml.
The minimum inhibitory concentration (MIC) was determined as the lowest concentration of compound that inhibited visible growth. A mirror reader was used to assist in determining the MIC endpoint. Compounds were evaluated against Gram-positive organisms, including
Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecalis and Enterococcus faecium.
In addition, compounds were evaluated against Gram-negative organisms including Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae and Stenotrophomonas maltophilia.
Each of the listed Examples, as identified in the present application was tested in the exemplified salt form. The tested Examples had a MIC <2 μg/ml against a strain of at least one of the organisms listed above. For at least one strain of every organism listed above, at least one Example had a MIC<2 μg/ml.
Mycobacterium tuberculosis H37Rv Inhibition Assay
The measurement of the minimum inhibitory concentration (MIC) for each tested compound was performed in 96 wells flat-bottom, polystyrene microtiter plates. Ten two- fold drug dilutions in neat DMSO starting at 400μM were performed. Five μl of these drug solutions were added to 95 μl of Middlebrook 7H9 medium. (Lines A-H, rows 1-10 of the plate layout). Isoniazid was used as a positive control, 8 two-fold dilution of
Isoniazid starting at 160 μgmT ' was prepared and 5 μl of this control curve was added to 95μl of Middlebrook 7H9 (Difco catalogue Ref. 271310) + ADC medium (Becton Dickinson Catalogue Ref. 211887). (Row 1 1 , lines A-H). Five μl of neat DMSO were added to row 12 (growth and Blank controls).
The inoculum was standardised to approximately 1x107 cfu/ml and diluted 1 in 100 in Middlebrook 7H9+ADC medium and 0.025% Tween 80 (Sigma P4780), to produce the final inoculum of H37Rv strain (ATCC25618). One hundred μl of this inoculum was added to the entire plate but G-12 and H-12 wells (Blank controls). All plates were placed in a sealed box to prevent drying out of the peripheral wells and they were incubated at 370C without shaking for six days. A resazurin solution was prepared by dissolving one tablet of resazurin (Resazurin Tablets for Milk Testing; Ref 330884Y VWR International Ltd) in 30 ml sterile PBS (phosphate buffered saline). 25 μl of this solution was added to each well. Fluorescence was measured (Spectramax M5
Molecular Devices, Excitation 530nm, Emission 590nm) after 48 hours to determine the MIC value.
The listed Examples 1-4 were tested in the Mycobacterium tuberculosis H37Rv inhibition assay. Examples 1 , 2 and 4 showed an MIC value of lower than 2.0 μg/ml. Example 3 showed an MIC value of > 2.5 μg/ml.

Claims

Claims
1. A compound of formula (I) or a pharmaceutically acceptable salt and/or N-oxide thereof:
wherein: one of Z1 and Z2 is CR1c and the other is CH or N;
R^a and R""3 are independently selected from hydrogen; halogen; cyano; (C-|.g)alkyl; (C-|.g)alkylthio; trifluoromethyl; trifluoromethoxy; carboxy; (C-|.g)alkoxy; hydroxy; hydroxy optionally substituted with (C-|.g)alkoxy-substituted(C-|.g)alkyl; (C-|_g)alkoxy- substituted(C-|.g)alkyl; hydroxy (C-|.g)alkyl; an amino group optionally N-substituted by one or two (C-|.g)alkyl, formyl, (C-|.g)alkylcarbonyl or (C-|.g)alkylsulphonyl groups; and aminocarbonyl wherein the amino group is optionally substituted by one or two (C-|_ 4)alkyl;
provided that R^ a and R-"3 are H when Z2 or Z^ is N, respectively;
R2 is hydrogen, (C-|_4)alkyl, or together with R^ forms Y as defined below; A is a group (i) selected from:
(ia) or (ib) in which: R3 is independently as defined for R^ a and R-"3 or is oxo and n is 1 or 2;
or A is a group (ii):
wherein
W1 , W2 and W3 are CR4R8 or \Λ/2 and W3 are CR4R8 and W^ represents a bond between W3 and N; X is O, CR4R8, or NR6; one R4 is independently as defined for R^ a and R-"3 and the remainder and R8 are hydrogen or one R4 and R8 are together oxo and the remainder are hydrogen; R6 is hydrogen or (C-|.g)alkyl; or together with R2 forms Y;
R7 is hydrogen; halogen; (C-|.g)alkoxy; hydroxy; or (C-|.g)alkyl; Y is CR4R8CH2; CH2CR4R8; (C=O); CR4R8; CR4R8(C=O); or (C=O)CR4R8; where R4 and R8 are independently as defined above; or when X is CR4R8, R8 and R7 together represent a bond;
U is selected from CO and CH2; and
R5 is an optionally substituted bicyclic carbocyclic or heterocyclic ring system (B):
containing up to four heteroatoms in each ring in which at least one of rings (a)and (b) is aromatic; χ1 is C or N when part of an aromatic ring, or CR^ when part of a non-aromatic ring; X2 is N, NR13, O, S(O)X, CO or CR^ when part of an aromatic or non-aromatic ring or may in addition be CR14R15 when part of a non aromatic ring; χ3 and X^ are independently N or C; γ1 is a 0 to 4 atom linker group each atom of which is independently selected from N, NR13, O, S(O)X, CO and CR^ when part of an aromatic or non-aromatic ring or may additionally be when part of a non aromatic ring;
Y2 is a 2 to 6 atom linker group, each atom of Y2 being independently selected from N, NR13; O, S(O)X, CO, CR^ when part of an aromatic or non-aromatic ring or may additionally be CR14R15 when part of a non aromatic ring; each of R^ and R^ js independently selected from: H; (C-|_4)alkylthio; halo; carboxy(C-|_4)alkyl; (C-|_4)alkyl; (C-|_4)alkoxycarbonyl; (C-|_4)alkylcarbonyl; (C-|_4)alkoxy (C-|_4)alkyl; hydroxy; hydroxy(C-|_4)alkyl; (C-|_4)alkoxy; nitro; cyano; carboxy; amino or aminocarbonyl optionally mono- or di-substituted by (C-|_4)alkyl; or R14 and R^ may together represent oxo; each R13 JS independently H; trifluoromethyl; (C-|_4)alkyl optionally substituted by hydroxy, (C-|.g)alkoxy, (C-|.g)alkylthio, halo or trifluoromethyl; (C2-4)alkenyl; (C-|_
4)alkoxycarbonyl; (C-|_4)alkylcarbonyl; (C-|.g)alkylsulphonyl; aminocarbonyl wherein the amino group is optionally mono or disubstituted by (C-|_4)alkyl; and each x is independently O, 1 or 2.
2. A compound according to claim 1 wherein: Z1 is CR1c and Z2 is CH; Z1 is CH and Z2 is CR1c; Z1 is CR1c and Z2 is N; or
Z1 is N and Z2 is CR1c.
3. A compound according to any preceding claim wherein R-I a is hydrogen and R""3 is hydrogen.
4. A compound according to any preceding claim wherein R^ 0 is methyl.
5. A compound according to any preceding claim wherein A is (ia), n is 1 and R3 is H or hydroxy in the 3-position, A is (ii), X is CR4R8 and R8 is H and R4 is H or OH, or A is (ii), X is O, R7 is H and W1 , W2 and W3 are each CH2.
6. A compound according to claim 5 wherein A is piperidin-4-yl or pyrrolidin-4- ylmethyl.
7. A compound according to any preceding claim wherein U is CH2.
8. A compound according to any preceding claim wherein R^ is an aromatic heterocyclic ring (B) having 8-11 ring atoms including 2-4 heteroatoms of which at least one is N or NR^3 jn which Y2 contains 2-3 heteroatoms, one of which is S and 1-2 are
N, with one N bonded to X3, or the heterocyclic ring (B) has ring (a) aromatic selected from optionally substituted benzo, pyrido, pyridazino and pyrimidino and ring (b) non aromatic and Y2 has 3-5 atoms, including at least one heteroatom, with O, S, CH2 or
NR^3 bonded to X^ where R^3 is hydrogen or other than hydrogen, and either NHCO bonded via N to X3, or O, S, CH2 or NH bonded to X3.
9. A compound according to any preceding claim wherein R^ is selected from: 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1 ,4]oxazin-6-yl,
3-oxo-3,4-dihydro-2/-/-pyrido[3,2-b][1 ,4]thiazin-6-yl,
2,3-dihydro-[1 ,4]dioxino[2,3-c]pyridin-7-yl,
[1 ,3]oxathiolo[5,4-c]pyridin-6-yl,
6-fluoro-2,3-dihydro-1 ,4-benzodioxin-7-yl, 2,3-dihydro[1 ,4]oxathiino[2,3-c]pyridin-7-yl,
3,4-dihydro-2/-/-pyrano[2,3-c]pyridin-6-yl,
5-fluoro-2,3-dihydro-1 ,4-benzodioxin-7-yl,
5-carbonitro-2,3-dihydro-1 ,4-benzodioxin-7-yl and 2,3-dihydro-benzo[1 ,4]dioxin-6-yl.
10. A compound according to claim 1 selected from: (1R)-1-({4-[(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1- piperidinyl}methyl)-6-methyl-1 ,2-dihydro-4H,9H-imidazo[1 ,2,3-/y]-1 ,8-naphthyridine-4,9- dione;
(1/?)-1-({4-[(2,3-dihydro[1 ,4]oxathiino[2,3-c]pyridin-7-ylmethyl)amino]-1- piperidinyl}methyl)-6-methyl-1 ,2-dihydro-4H,9H-imidazo[1 ,2,3-/y]-1 ,8-naphthyridine-4,9- dione; (1/?)-1-({4-[(2,3-dihydro[1 ,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1- piperidinyl}methyl)-6-methyl-1 ,2-dihydro-4H,9H-imidazo[1 ,2,3-/y]-1 ,8-naphthyridine-4,9- dione; and
(1/?)-6-methyl-1-({4-[([1 ,3]oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1- piperidinyl}methyl)-1 ,2-dihydro-4H,9H-imidazo[1 ,2,3-/y]-1 ,8-naphthyridine-4,9-dione; or a pharmaceutically acceptable salt and/or N-oxide thereof.
11. A compound according to claim 10 selected from: (1/?)-1-({4-[(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1- piperidinyl}methyl)-6-methyl-1 ,2-dihydro-4H,9H-imidazo[1 ,2,3-/y]-1 ,8-naphthyridine-4,9- dione hydrochloride;
(1/?)-1-({4-[(2,3-dihydro[1 ,4]oxathiino[2,3-c]pyridin-7-ylmethyl)amino]-1- piperidinyl}methyl)-6-methyl-1 ,2-dihydro-4H,9H-imidazo[1 ,2,3-/y]-1 ,8-naphthyridine-4,9- dione hydrochloride;
(1/?)-1-({4-[(2,3-dihydro[1 ,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1- piperidinyl}methyl)-6-methyl-1 ,2-dihydro-4H,9H-imidazo[1 ,2,3-/y]-1 ,8-naphthyridine-4,9- dione hydrochloride; and
(1/?)-6-methyl-1-({4-[([1 ,3]oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1- piperidinyl}methyl)-1 ,2-dihydro-4H,9H-imidazo[1 ,2,3-/y]-1 ,8-naphthyridine-4,9-dione hydrochloride.
12. A method of treatment of bacterial infections in mammals, particularly in man, which method comprises the administration to a mammal in need of such treatment an effective amount of a compound according to any preceding claim.
13. The use of a compound according to any of claims 1 to 11 in the manufacture of a medicament for use in the treatment of bacterial infections in mammals.
14. A compound according to any of claims 1 to 1 1 , for use in therapy.
15. A compound according to any of claims 1 to 1 1 , for use in the treatment of bacterial infections in mammals.
16. A pharmaceutical composition comprising a compound according to any of claims 1 to 1 1 and a pharmaceutically acceptable carrier.
EP09740103A 2008-10-17 2009-10-16 Tricyclic nitrogen compounds used as antibacterials Withdrawn EP2352734A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10627908P 2008-10-17 2008-10-17
PCT/EP2009/063610 WO2010043714A1 (en) 2008-10-17 2009-10-16 Tricyclic nitrogen compounds used as antibacterials

Publications (1)

Publication Number Publication Date
EP2352734A1 true EP2352734A1 (en) 2011-08-10

Family

ID=41361255

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09740103A Withdrawn EP2352734A1 (en) 2008-10-17 2009-10-16 Tricyclic nitrogen compounds used as antibacterials

Country Status (4)

Country Link
US (1) US20110275661A1 (en)
EP (1) EP2352734A1 (en)
JP (1) JP2012505866A (en)
WO (1) WO2010043714A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2834973T3 (en) 2010-05-04 2021-06-21 Alkermes Pharma Ireland Ltd Process for the synthesis of oxidized lactam compounds
CA2840060A1 (en) * 2011-06-27 2013-01-03 Kyorin Pharmaceutical Co., Ltd. Bridged bicyclic compounds for the treatment of bacterial infections
US10702521B2 (en) * 2014-08-22 2020-07-07 Glaxosmithkline Intellectual Property Development Limited Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones
CN111892601B (en) * 2020-09-01 2023-09-26 陕西大美化工科技有限公司 Pyridopyrazolocinnoline compound and preparation method and application thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2798656B1 (en) 1999-09-17 2004-12-17 Aventis Pharma Sa DERIVATIVES OF QUINOLYL PROPYL PIPERIDINE, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM
US6624159B2 (en) * 2000-07-12 2003-09-23 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
EP1306038B1 (en) 2000-07-21 2005-12-21 Ljudmila Petrovna Maljuk Plate for a stand-up meal
EP1305308B1 (en) 2000-07-26 2006-12-20 Smithkline Beecham Plc Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
FR2816618B1 (en) 2000-11-15 2002-12-27 Aventis Pharma Sa HETEROCYCLYLALCOYL PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
EP1345903A1 (en) 2000-12-21 2003-09-24 Ciba SC Holding AG Crystalline forms of cerivastatin sodium
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
US7312212B2 (en) 2002-01-29 2007-12-25 Glaxo Group Limited Aminopiperidine derivatives
EP1470131A2 (en) 2002-01-29 2004-10-27 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
TW200406413A (en) 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
AR040336A1 (en) 2002-06-26 2005-03-30 Glaxo Group Ltd PIPERIDINE COMPOUND, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND PROCEDURE TO PREPARE SUCH COMPOUND
GB0217294D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
FR2844270B1 (en) 2002-09-11 2006-05-19 Aventis Pharma Sa QUINOLYL PROPYL PIPERIDINE DERIVATIVES, THEIR PROCESS AND PREPARATION INTERMEDIATES AND THE COMPOSITIONS CONTAINING THEM
FR2844268B1 (en) 2002-09-11 2004-10-22 Aventis Pharma Sa QUINOLYL PROPYL PIPERIDINE DERIVATIVES, PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION, AND COMPOSITIONS CONTAINING THEM
EP1551829B1 (en) 2002-10-10 2010-04-07 Morphochem Aktiengesellschaft Für Kombinatorische Chemie Novel compounds with antibacterial activity
EP1560488B1 (en) 2002-11-05 2010-09-01 Glaxo Group Limited Antibacterial agents
US7232832B2 (en) 2002-11-05 2007-06-19 Smithkline Beecham Corporation Antibacterial agents
AR042486A1 (en) 2002-12-18 2005-06-22 Glaxo Group Ltd QUINOLINE AND NAFTIRIDINE COMPOSITE HALOSUSTITUDED IN POSITION 3, PROCEDURE TO PREPARE THE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE SUCH COMPOSITION.
TW200507841A (en) 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
FR2852954B1 (en) 2003-03-28 2006-07-14 Aventis Pharma Sa QUINOLINE-4-SUBSTITUTED DERIVATIVES, METHODS AND PREPARATION INTERMEDIATES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE10316081A1 (en) 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie New compounds with antibacterial activity
WO2004104000A1 (en) 2003-05-23 2004-12-02 Japan Tobacco Inc. Tricyclic condensed ring compound and medical use thereof
FR2858619B1 (en) 2003-08-08 2006-12-22 Aventis Pharma Sa QUINOLINE-4-SUBSTITUTED DERIVATIVES, METHODS AND PREPARATION INTERMEDIATES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2867472B1 (en) 2004-03-12 2008-07-18 Aventis Pharma Sa QUINOLINE-4-SUBSTITUTED DERIVATIVES, METHODS AND PREPARATION INTERMEDIATES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2006002047A2 (en) 2004-06-15 2006-01-05 Glaxo Group Limited Antibacterial agents
FR2872164B1 (en) 2004-06-29 2006-11-17 Aventis Pharma Sa QUINOLINE-4-SUBSTITUTED DERIVATIVES, PROCESS AND PREPARATION INTERMEDIATES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
JP2008505920A (en) 2004-07-08 2008-02-28 グラクソ　グループ　リミテッド Antibacterial agent
US20080194547A1 (en) 2004-07-09 2008-08-14 Glaxo Group Limited Antibacterial Agents
JP2008506695A (en) 2004-07-13 2008-03-06 グラクソ　グループ　リミテッド Antibacterial agent
US20070270417A1 (en) 2004-07-22 2007-11-22 Glaxo Group Limited Antibacterial Agents
WO2006017468A2 (en) 2004-08-02 2006-02-16 Glaxo Group Limited Antibacterial agents
JP2008509222A (en) 2004-08-09 2008-03-27 グラクソ グループ リミテッド Antibacterial agent
DE102004041163A1 (en) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie New compounds with antibacterial activity
JP4887297B2 (en) 2004-09-24 2012-02-29 アクテリオン ファーマシューティカルズ リミテッド New bicyclic antibiotics
DE602005021133D1 (en) 2004-10-05 2010-06-17 Actelion Pharmaceuticals Ltd NEW PIPERIDINE ANTIBIOTICS
JP5314244B2 (en) 2004-10-27 2013-10-16 富山化学工業株式会社 Novel nitrogen-containing heterocyclic compounds and salts thereof
JP2008528586A (en) 2005-01-25 2008-07-31 グラクソ グループ リミテッド Antibacterial agent
JP2008528598A (en) 2005-01-25 2008-07-31 グラクソ グループ リミテッド Antibacterial agent
WO2006081182A2 (en) 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
US7511035B2 (en) 2005-01-25 2009-03-31 Glaxo Group Limited Antibacterial agents
EP1845995A4 (en) 2005-01-25 2010-03-03 Glaxo Group Ltd Antibacterial agents
WO2006099884A1 (en) 2005-03-24 2006-09-28 Actelion Percurex Ag Beta-aminoalcohol antibiotics
JP5023054B2 (en) 2005-03-31 2012-09-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Bicyclic pyrazole compounds as antibacterial agents
MX2007014507A (en) 2005-05-24 2008-02-07 Astrazeneca Ab Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity.
ATE441645T1 (en) 2005-05-25 2009-09-15 Actelion Pharmaceuticals Ltd NEW ANTIBIOTIC DERIVATIVES
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
EP1900732A4 (en) 2005-06-24 2009-11-18 Toyama Chemical Co Ltd NOVEL HETEROCYCLIC NITROGENIC COMPOUND AND SALT THEREOF
WO2007016610A2 (en) 2005-08-02 2007-02-08 Glaxo Group Limited Antibacterial agents
ES2340531T3 (en) 2005-10-21 2010-06-04 Glaxo Group Limited PERI-CONDENSED TRICYCLES USEFUL AS ANTIBACTERIAL AGENTS.
WO2007053056A1 (en) * 2005-10-31 2007-05-10 Adnan Muhatdinovich Shemelev Game roulette
ATE465163T1 (en) 2005-12-22 2010-05-15 Glaxo Group Ltd HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIAL AGENTS
WO2007118130A2 (en) 2006-04-06 2007-10-18 Glaxo Group Limited Antibacterial agents
EP2001887B1 (en) 2006-04-06 2010-09-15 Glaxo Group Limited Pyrrolo-quinoxalinone derivatives as antibacterials
GB0608263D0 (en) * 2006-04-26 2006-06-07 Glaxo Group Ltd Compounds
JP2009539807A (en) 2006-06-09 2009-11-19 グラクソ グループ リミテッド Substituted 1-methyl-1H-quinolin-2-one and 1-methyl-1H-1,5-naphthyridin-2-one as antibacterial agents
GB0613208D0 (en) * 2006-07-03 2006-08-09 Glaxo Group Ltd Compounds
EP1992628A1 (en) 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
GB0705672D0 (en) * 2007-03-23 2007-05-02 Glaxo Group Ltd Compounds
AU2008240764C1 (en) * 2007-04-20 2011-10-20 Glaxo Group Limited Tricyclic nitrogen containing compounds as antibacterial agents
GB0800367D0 (en) * 2008-01-09 2008-02-20 Glaxo Group Ltd Compounds
CA2725726A1 (en) * 2008-05-23 2009-11-26 Glaxo Group Limited Tricyclic nitrogen containing compounds and their use as antibacterials
WO2009141399A1 (en) 2008-05-23 2009-11-26 Glaxo Group Limited Tricyclic nitrogen containing compounds and their use as antibacterials

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2010043714A1 *

Also Published As

Publication number Publication date
WO2010043714A1 (en) 2010-04-22
US20110275661A1 (en) 2011-11-10
JP2012505866A (en) 2012-03-08

Similar Documents

Publication Publication Date Title
US11229646B2 (en) Method for treating gonorrhea with (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-C]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2A,5,8A-triazaacenaphthylene-3,8-dione
JP5389013B2 (en) Tricyclic nitrogen-containing compounds as antibacterial agents
US7709483B2 (en) Pyrrolo-quinoxalinone derivatives as antibacterials
US20100004230A1 (en) Azatricyclic compounds and their use
EP2007377A2 (en) Antibacterial agents
JP2010521518A (en) Compound
US20110009394A1 (en) Tricyclic nitrogen compounds and their use as antibacterial agents
EP2352734A1 (en) Tricyclic nitrogen compounds used as antibacterials
JP2010524890A (en) Compound
ES2351377T3 (en) TRICYCLIC COMPOUNDS CONTAINING NITROGEN AS ANTIBACTERIAL AGENTS.
HK1138000B (en) Tricyclic nitrogen containing compounds as antibacterial agents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110513

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20120502

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GLAXO GROUP LIMITED

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130702